<SUBMISSION>
<ACCESSION-NUMBER>0001140361-06-016662
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>4
<PERIOD>20061116
<ITEMS>7.01
<ITEMS>9.01
<FILING-DATE>20061117
<DATE-OF-FILING-DATE-CHANGE>20061116
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>ALR TECHNOLOGIES INC
<CIK>0001087022
<ASSIGNED-SIC>3669
<IRS-NUMBER>880225807
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-30414
<FILM-NUMBER>061224479
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>114M REYNOLDA VILLAGE
<CITY>WINSTON-SALEM
<STATE>NC
<ZIP>27106
<PHONE>(336) 722-2254
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>114M REYNOLDA VILLAGE
<CITY>WINSTON-SALEM
<STATE>NC
<ZIP>27106
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>ALR TECHNOLOGIES INC 8-K 11-16-2006
<TEXT>
<html>
  <head>
    <title>
      ALR Technologies Inc 8-K 11-16-2006
</title>
<!-- Licensed to: EDGARfilings-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Washington,
      D.C. 20549</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
      <div>
        <hr style="COLOR: black" align="center" noshade size="2" width="40%">
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>FORM
      8-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>CURRENT
      REPORT</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Pursuant
      to Section 13 or 15(d) of the</strong></font><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Securities
      Exchange Act of 1934.</strong></font><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Date
      of Report: November 16, 2006</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Date
      of
      earliest event reported)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman"><strong>ALR
      Technologies, Inc.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Exact
      name of registrant as specified in its charter)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div align="left">
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="top" width="32%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>NEVADA</strong></font></div>
            </td>
            <td valign="top" width="2%">&#160;</td>
            <td valign="top" width="32%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>000-30414</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
            </td>
            <td valign="top" width="2%">&#160;</td>
            <td valign="top" width="32%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>88-0225807</strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="32%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(State
                or other jurisdiction of incorporation) </font></div>
            </td>
            <td valign="top" width="2%">&#160;</td>
            <td valign="top" width="32%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Commission
                File Number)</font></div>
            </td>
            <td valign="top" width="2%">&#160;</td>
            <td valign="top" width="32%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(IRS
                Employer Identification Number) </font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="32%">&#160;</td>
            <td valign="top" width="2%">&#160;</td>
            <td valign="top" width="32%">&#160;</td>
            <td valign="top" width="2%">&#160;</td>
            <td valign="top" width="32%">&#160;</td>
          </tr>
          <tr>
            <td valign="middle" width="32%">&#160;</td>
            <td align="left" valign="top" width="2%">&#160;</td>
            <td align="left" valign="middle" width="32%">&#160;</td>
            <td valign="top" width="2%">&#160;</td>
            <td valign="middle" width="32%">&#160;</td>
          </tr>
          <tr>
            <td valign="middle" width="32%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>114M
                REYNOLDA VILLAGE, WINSTON-SALEM, NC</strong></font></div>
            </td>
            <td align="left" valign="top" width="2%">&#160;</td>
            <td align="left" valign="middle" width="32%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
            </td>
            <td valign="top" width="2%">&#160;</td>
            <td valign="middle" width="32%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>27106</strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="middle" width="32%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
                of principal executive offices) </font></div>
            </td>
            <td align="left" valign="top" width="2%">&#160;</td>
            <td align="left" valign="middle" width="32%">&#160;</td>
            <td valign="top" width="2%">&#160;</td>
            <td valign="middle" width="32%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Zip
                Code) </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="middle" width="83%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(336)722-2254</strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="middle" width="83%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Registrant's
                telephone number, including area code) </font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="middle" width="83%">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="middle" width="83%">&#160;</td>
          </tr>
          <tr>
            <td valign="middle" width="83%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Not
                Applicable</strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="middle" width="83%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Former
                Name or Former Address, if changed since last
                report)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Check
      the
      appropriate box below if the Form 8-K filing is intended to simultaneously
      satisfy the filing obligation of the registrant under any of the following
      provisions:</font></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 18pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Written
                communications pursuant to Rule 425 under the Securities Act (17
                CFR
                230.425)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 18pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Soliciting
                material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
                240.14a-12)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 18pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pre-commencement
                communications pursuant to Rule 14d-2(b) under the Exchange Act (17
                CFR
                240.14d-2(b)) </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 18pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pre-commencement
                communications pursuant to Rule 13e-4(c) under the Exchange Act (17
                CFR
                240.13e-4(c)) </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div>&#160;</div>
    <div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
    </div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Item
      7.01. Regulation FD Disclosure</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Corporate
      Profile</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Item
      9.01. Financial Statements and Exhibits</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(a)
      Financial statements:</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">None</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(b)
      Pro forma financial information:</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">None</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(c)
      Shell company transactions:</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">None</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(d)
      Exhibits</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">99.1</font></div>
    <div><br></div>
    <div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
    </div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURE</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, the registrant
      has
      duly caused this report to be signed on its behalf by the undersigned hereunto
      duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div align="left">
      <table border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="46%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dated:
                November 16, 2006</font></div>
            </td>
            <td align="left" valign="top" width="4%">&#160;</td>
            <td align="left" colspan="2" valign="top" width="46%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ALR
                TECHNOLOGIES, INC.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
            </td>
            <td align="left" valign="top" width="4%">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="top" width="46%">&#160;</td>
            <td align="left" valign="top" width="4%">&#160;</td>
            <td align="left" valign="top" width="4%">&#160;</td>
            <td align="left" valign="top" width="42%">&#160;</td>
            <td align="left" valign="top" width="4%">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="top" width="46%">&#160;</td>
            <td align="left" valign="top" width="4%">&#160;</td>
            <td align="left" valign="top" width="4%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:</font></div>
            </td>
            <td align="left" valign="top" width="42%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/
                Sidney Chan</font></div>
            </td>
            <td align="left" valign="top" width="4%">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="top" width="46%">&#160;</td>
            <td align="left" valign="top" width="4%">&#160;</td>
            <td align="left" valign="top" width="4%">&#160;</td>
            <td align="left" valign="top" width="42%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Sidney
                Chan</font></div>
            </td>
            <td align="left" valign="top" width="4%">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="top" width="46%">&#160;</td>
            <td align="left" valign="top" width="4%">&#160;</td>
            <td align="left" valign="top" width="4%">&#160;</td>
            <td align="left" valign="top" width="42%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Chief
                Executive Officer and a member of the Board of
                Directors</em></font></div>
            </td>
            <td align="left" valign="top" width="4%">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
    </div>
    <div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Exhibit
        Index</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td valign="top" width="48%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Exhibit
                  No.</u></strong></font></div>
              </td>
              <td width="4%">&#160;</td>
              <td valign="top" width="48%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Description</u></strong></font></div>
              </td>
            </tr>
            <tr>
              <td valign="top" width="48%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="ex99_1.htm">99.1</a></font></div>
              </td>
              <td width="4%">&#160;</td>
              <td valign="top" width="48%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Corporate
                  Profile date November 2006</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;

        <div>
          <hr style="COLOR: black" align="left" noshade size="2" width="100%">
        </div>
      </div>
    </div>
  </body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title>
      Exhibit 99.1
</title>
<!-- Licensed to: EDGARfilings-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div>
      <div>
        <hr style="COLOR: black" align="left" noshade size="4" width="100%">
      </div>
    </div><br>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="35%">&#160;</td>
            <td align="left" valign="top" width="2%">&#160;</td>
            <td align="left" valign="top" width="16%">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="35%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman">Corporate
                Profile</font></div>
            </td>
            <td align="left" valign="top" width="2%">&#160;</td>
            <td align="left" valign="top" width="16%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><img src="logo.jpg" alt=""></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ALR
                Technologies Inc.&#160;&#160;&#160;
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div>
          <table cellpadding="0" cellspacing="0" width="100%">

              <tr>
                <td align="left" valign="top" width="26%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>November
                    2006</strong></font></div>
                </td>
                <td align="right" valign="top" width="2%">&#160;</td>
                <td align="right" valign="top" width="64%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>http://www.alrt.com</strong></font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 7.2pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br>
          <div align="left">
            <table cellpadding="0" cellspacing="0" width="100%">

                <tr>
                  <td align="left" valign="bottom" width="15%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SYMBOL/EXCHANGE</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">RECENT
                      PRICE</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">52
                      WEEK RANGE</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SHARES
                      OUT.</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SHARES
                      FLOAT</font></div>
                  </td>
                  <td valign="top" width="2%">&#160;</td>
                  <td valign="bottom" width="15%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ALRT
                      / OTCBB</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$0.10</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$.045
                      - $.22</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">76.1
                      MM</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">35.3
                      MM</font></div>
                  </td>
                  <td valign="top" width="2%">&#160;</td>
                  <td valign="middle" width="66%">
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;<img src="chart.jpg" alt=""></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="bottom" width="15%">
                    <div style="MARGIN-LEFT: 99pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
                  </td>
                  <td valign="top" width="2%">&#160;</td>
                  <td valign="bottom" width="15%">
                    <div style="MARGIN-LEFT: 81pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  </td>
                  <td valign="top" width="2%">&#160;</td>
                  <td valign="top" width="66%">&#160;</td>
                </tr>

            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Corporate
          Summary</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ALR
          Technologies Inc. (OTCBB: ALRT) is a pioneer in the emerging market for
          the home
          health management and disease management industry. While medical researchers
          and
          pharmaceutical companies have been effective in developing treatments to
          manage
          many diseases and health issues, poor medication compliance at home, mainly
          forgetting when and which medication to take, has rendered the treatments
          less
          effective. The growing problem of patient non-adherence to medical treatments
          contributes to more than $140 billion dollars annually in excess health
          care
          costs. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Health
          care costs in the US currently account for 15% of the gross domestic product
          and
          is expected to reach 25% by 2020.</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ALRT
          has
          developed a technology-based "clinically proven" system, the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Constant
          Health Companion</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8482;
to
          address the problem of patient non-adherence. The </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Constant
          Health Companion</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          will
          serve as a medication reminder for the patients at home, monitor the patients'
          compliance to prescribed medical treatments and, if necessary, facilitate
          timely
          intervention by their health care providers. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At
          the
          present time, current US health management practices fall far short as
          patients
          are left largely on their own after they are discharged from the hospital,
          leave
          the medical clinic or after the case manager leaves their homes. The
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Constant
          Health Companion</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          will
          enable remote and continued oversight of the patients by their health care
          providers. The system will provide the necessary information for health
          care
          providers to improve treatment adherence by their patients resulting in
          more
          favorable health outcomes and containment of health care costs. ALRT is
          focused
          on becoming the leader and driver of growth for the emerging health management
          compliance market. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">With
          the
          ALRT health management products and systems, health care providers can
          now
          remind patients what to do at the appropriate times, determine patients'
          compliance and intervene when necessary. Improving compliance and intervening
          on
          a real time basis will result in better health outcome and reduce the overall
          cost of healthcare. Accordingly, use of the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Constant
          Health Companion</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          will
          realize significant return on investment. Furthermore, the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Constant
          Health Companion</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          system
          will provide valuable information for financial decision-making. Insurance
          providers can monitor plan members' compliance and adjust the pricing of
          their
          coverage based on adherence by the members to prescribed health management
          programs. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          the
          course of developing the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Constant
          Health Companion</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          over the
          past five years, the company has also developed other spin-off compliance
          reminder products such as the ALRT PC 200, and other specialized products
          targeting specific health care needs. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ALRT
          has
          recently completed in-market pilots and trials with patients suffering
          from
          chronic conditions such as congestive heart failure, diabetes, organ transplant,
          HIV/AIDS as well as with assisted living organizations and Medicaid patients.
          Companies that participated in the pilots reported significant return on
          investment and improved health outcome results. These companies are also
          committing to use the ALRT system in their business operations. ALRT is
          starting
          its first full manufacturing run for product delivery in January
          2007.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>RECENT
          HEADLINES</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Nov
          8, 2006</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          - ALR
          Tech&#8217;s Constant Hlth Companion to Fill a Serious Gap in Current Health Mgmt
          Practices Making Healthcare Cost Reduction a Reality</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Oct
          30, 2006</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          - Apple
          Patch Community Receives Invitation to Present the ALRT500 Compliance System
          at
          the 2006 Institute for Behavioral Health Informatics</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Oct
          23, 2006</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          - Heart
          Transplant Patient Reports Significant Results With Medication and Treatment
          Compliance Using the ALRT500 Home Health Management System</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Oct
          18, 2006</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          -
          Medicaid Asthma Patients to Utilize the ALRT500 Health Mgmt System</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Aug
          24, 2006</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          -
          Medicaid Group Grants PageMinder Approval for Use of ALRT500 Health Mgmt
          Product
          With Chronic Patients</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>In
          an abstract based on a Columbia University Clinical Trial, presented to
          the 12th
          World AIDS Conference in Geneva, ALRT&#8217;s earlier version of the PC100&#8482; was shown
          to improve the frequency of patients taking 100% of their medication doses
          by
          97% and to improve the frequency of patients taking 100% of their medication
          doses at the correct time of day by 168%, which in turn, improved the overall
          health outcome of the study participants. </em></strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="left">
            </div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
            </div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right">
            </div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div>
          <table cellpadding="0" cellspacing="0" width="100%">

              <tr>
                <td align="left" valign="top" width="61%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Corporate
                    Profile - ALR Technologies, Inc.</strong></font></div>
                </td>
                <td align="left" valign="top" width="10%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Page
                    2</strong></font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Investment
          Highlights</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Documented
          Emerging Marketplace</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$140
          billion in healthcare costs are reported due to noncompliance of medical
          treatments and ALRT has the answers to solve this problem. Disease Management,
          Health Insurance Payers and Case Management companies are now looking to
          find a
          solution for this problem. Limiting factors such as cost, ease of use,
          and
          portability have been overcome by ALRT with their system.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Industry
          Leader</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ALRT
          has
          established itself as a pioneer in the disease management compliance
          marketplace, with a complete variety of medication compliance reminders
          and
          monitors. The ALRT systems can be monitored by a healthcare provider, homecare
          companies or family members and offer the essentials such of affordability
          and
          ease of use which are necessary to develop this market.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Significant
          Cost Over Competition</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          marketplace clearly has tremendous potential and there are only a handful
          of
          companies trying to service it. ALRT&#8217;s products and services cost to the
          consumer is at least 31% lower than the next least expensive system, with
          the
          company still generating healthy margins.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Patent-pending
          Technology</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ALRT
          is
          the only company with a Nebulizer Monitoring System; this monitoring System
          is
          patent-pending and allows the company to dominate a marketplace of 16 million
          people suffering from Chronic Obstructive Pulmonary Disease (COPD) as well
          as
          applicability to the millions of people who suffer from acute asthma. Patents
          received apply to the single button, ease of use features that are part
          of each
          of the ALRT products and systems.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Constant
          Health Companion&#8482; and Monitoring Enters Commercialization
          Phase</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ALRT
          has
          completed its internal pilot testing on the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Constant
          Health Companion</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          system
          and has now finalized in-market pilot programs with several commercial
          disease
          management and homecare service companies. The first full-scale manufacturing
          run is scheduled for delivery in January 2007.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>History</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Founded
          in 1998, and incorporated under the laws of the State of Nevada, the company
          was
          established to address a growing need in the disease management industry;
          that
          need being patients&#8217; adherence with medications and other disease management
          activities. Noncompliance is a world-wide problem of striking magnitude.
          Having
          focused their efforts on the development of the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Constant
          Health Companion</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          and the
          Home Health System (a disease management monitoring system) the company
          also
          successfully made available the ALRT Med Reminder in 2003 soon followed
          by the
          ALRT PC100 as well as monthly reminders for veterinary pharmaceuticals
          for the
          prevention of heartworm disease in dogs and cats. The ALRT PC200, a second
          generation of the PC100 was designed in early 2005 in response to specific
          needs
          addressed by companies providing mail order medications and disease management
          services. The company has now completed development of the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Constant
          Health Companion</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          and
          monitoring system and full-scale manufacturing is to begin in the fall
          of 2006.
</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">While
          developing the ALRT compliance system, the company has also successfully
          secured
          patent protection and patent-pending status for a series of
          products.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div align="left">
          <table border="1" bordercolor="black" cellpadding="2" cellspacing="0" width="100%">

              <tr bgcolor="#cceeff">
                <td valign="middle" width="45%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Patent</font></div>
                </td>
                <td valign="middle" width="55%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Description</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="bottom" width="45%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Provisional
                    Patent App. Serial No. 60/652,237 </font></div>
                </td>
                <td align="left" valign="bottom" width="55%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Medical
                    Reminder Device Suited for Use with Nebulizer</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="bottom" width="45%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Nonprovisional
                    Patent App. Serial No. 10/462,096 </font></div>
                </td>
                <td align="left" valign="bottom" width="55%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Portable
                    Programmable Medical Alert Device</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="bottom" width="45%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Claims
                    Benefit of Provisional Patent App. Serial No. 60/388,264</font></div>
                </td>
                <td align="left" valign="bottom" width="55%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Portable
                    Programmable Medical Alert Device</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="bottom" width="45%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Provisional
                    Patent App.Serial No. 60/388,264 </font></div>
                </td>
                <td align="left" valign="bottom" width="55%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Portable
                    Programmable Medical Alert Device</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="bottom" width="45%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">US
                    Patent D446,740</font></div>
                </td>
                <td align="left" valign="bottom" width="55%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ornamental
                    Design of a Medication Alert Device in the Shape of a
                    Heart</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="bottom" width="45%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">US
                    Patent D446,739</font></div>
                </td>
                <td align="left" valign="bottom" width="55%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ornamental
                    Design of a Medication Alert Device in the Shape of a Dog
                    Bone</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="bottom" width="45%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">US
                    Design Patent D447,074</font></div>
                </td>
                <td align="left" valign="bottom" width="55%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ornamental
                    Design of a Medication Alert Device in the Shape of a Stylized
                    Paw</font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="left">
            </div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
            </div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right">
            </div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div>
          <table cellpadding="0" cellspacing="0" width="100%">

              <tr>
                <td align="left" valign="top" width="61%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Corporate
                    Profile - ALR Technologies, Inc.</strong></font></div>
                </td>
                <td align="left" valign="top" width="10%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Page
                    3</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Management
          and Directors</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Sidney
          S. Chan</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mr.
          Chan,
          Chairman and Chief Executive Officer of ALR Technologies Inc. has made
          a
          significant contribution to the Company since first becoming involved in
          August
          1997. He has assisted the company&#8217;s financing and its evolution into a public
          company. Most importantly, he has also directed the company&#8217;s product
          development. Mr. Chan has extensive relationships with Hong Kong area based
          technology and electronic manufacturers----helping assure the availability
          of
          low cost manufacturing and materials procurement. Mr. Chan is an engineer
          and
          obtained his Bachelor of Engineering (Mining) degree with distinction in
          Mineral
          Economics from McGill University in 1973.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Stan
          Cruitt</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stan
          Cruitt joined ALR Technologies as President in 2000, bringing with him
          more than
          20 years of experience in the pharmaceutical industry. He became President
          at a
          key point in the company&#8217;s history, when ALRT was evaluating its products and
          considering innovative uses for medication reminders throughout the healthcare
          community.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mr.
          Cruitt has extensive experience in the pharmaceutical industry, where he
          has
          held numerous positions ranging from serving as a marketing research analyst
          with Merck to top marketing and management positions with Ciba and Novartis.
          In
          1996, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Newsweek
          </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">and
          </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Advertising
          Age </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">recognized
          him as one of the top marketers in the United States. Mr. Cruitt&#8217;s experience at
          building brands, markets and business is a needed fit for ALRT. Mr. Cruitt
          received his undergraduate degree from Southern Illinois University and
          received
          academic honors during graduate study.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Jaroslav
          V. Tichy, Ph D</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Since
          December, 2000, Dr. Tichy has been Vice President of Technology for the
          company.
          From 1984 through 2000, Dr. Tichy was a Systems Design Specialist with
          Weir-Jones Engineering Consultants Ltd. Dr. Tichy has conducted research
          and
          lectured in a wide range of areas including asynchronous switching theory,
          signal theory and pattern recognition. In addition, he has been involved
          in a
          number of development projects including analog, digital and mixed circuit
          design, digital signal processing and microprocessor and microcontroller
          based
          systems. Dr. Tichy received both his Ph.D and MSc. Degrees in Computer
          Technology from the Technical University in Brno Czech Republic.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Advisory
          Board</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Michael
          Baumgarner, PhD</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chief
          Executive and President of Burke, Inc. - Dr. Baumgardner has been the President
          of Burke, Inc., since 1994 and CEO since 2004. Headquartered in Cincinnati,
          OH,
          Burke, Inc., is one of the premier international marketing research and
          consulting firms, with offices and affiliates in 40 countries.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Arnold
          da Silva</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Vice
          President and General Manager, Schenker of Canada Limited - Schenker of
          Canada
          Limited is one of the leading international providers of integrated logistics
          and freight-forwarding services at over 1,000 locations around the
          world.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>William
          Lorentz, M D</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dr.
          Lorentz is the Associate Chief of Professional Services at North Carolina
          Baptist Hospital and serves as Professor of Pediatrics of the Wake Forest
          University Medical School. Dr. Lorentz is also Medical Director, MedCost,
          Inc.,
          a leading PPO in North Carolina.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Betsy
          Pearce</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Vice
          President and Chief Operating Officer of Niblock Financial Systems, Inc.
          Niblock
          is one of the largest providers of banking equipment and financial systems
          software in the United States, with headquarters located in
          Winston-</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Salem,
          NC.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Ronald
          H. Small</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Vice
          President, Quality Outcomes and Chief Pharmacy Officer for Wake Forest
          University Baptist Medical Center. Ron is also Adjunct Professor of Pharmacy
          Practice with the University of North Carolina and Campbell schools of
          Pharmacy
          and Lecturer in Hospital Administration at Wake Forest University. Some
          of the
          many organizations he is a member of include: APhA (Fellow), ASHP (Fellow),
          ASPEN and ACCP. Ron has contributed to the professional body of knowledge
          on
          topics such as TQM, Pharmacoeconomics, and Pharmaceutical Care, including
          the
          concept of Continuity of Care. Ron currently serves on the Advisory Board
          of
          Premier Purchasing Partners, an organization representing over 1900 hospitals.
          </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="left">
            </div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
            </div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right">
            </div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div>
          <table cellpadding="0" cellspacing="0" width="100%">

              <tr>
                <td align="left" valign="top" width="62%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Corporate
                    Profile - ALR Technologies, Inc.</strong></font></div>
                </td>
                <td align="left" valign="top" width="10%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Page
                    4</strong></font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Market
          Potential</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">It
          is
          estimated that there are 110 million people in the US alone taking medications
          or treatments for chronic conditions. According to a 1997 Health Economics
          analysis by the University of Arizona&#8217;s School of Pharmacy, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>noncompliance
          of medication contributed nearly $77 billion in excess annual medical care
          cost.
          This number is thought to have exceeded $140 billion in
          2004.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          In 2005,
          a New England Journal of Medicine study confirmed that 33% to 69% of
          medication-related hospital admissions in the US are due to poor medication
          adherence, with a resultant cost of approximately $100 billion a year.
          The rate
          of non-compliance for a number of chronic diseases has been documented
          as
          follows:</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div align="center">
          <table cellpadding="0" cellspacing="0" width="40%">

              <tr>
                <td align="left" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Condition</strong></font></div>
                </td>
                <td align="right" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Non-compliance</strong></font></div>
                </td>
              </tr>
              <tr bgcolor="#cceeff">
                <td align="left" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Epilepsy</font></div>
                </td>
                <td align="right" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">30-50%</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Diabetes
                    </font></div>
                </td>
                <td align="right" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">40-50%</font></div>
                </td>
              </tr>
              <tr bgcolor="#cceeff">
                <td align="left" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Hypertension
                    </font></div>
                </td>
                <td align="right" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">40%&#160;&#160;&#160;&#160;&#160;&#160;
                    </font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Asthma
                    </font></div>
                </td>
                <td align="right" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">20%&#160;&#160;&#160;&#160;&#160;&#160;
                    </font></div>
                </td>
              </tr>
              <tr bgcolor="#cceeff">
                <td align="left" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Anticoagulants
                    </font></div>
                </td>
                <td align="right" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">30%&#160;&#160;&#160;&#160;&#160;&#160;
                    </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          next
          significant growth area in healthcare and the one area to help contain/reduce
          costs is health management compliance and monitoring. Currently, the marketplace
          for compliance monitoring is directed to heart disease and a select few
          of the
          other most severe ailments. The systems that are currently available are
          very
          narrow in their focus due to the highly targeted population, and high cost
          of
          the systems. Compliance and monitoring of health management treatments,
          medications and other activities have significant untapped market size
          potential, as awareness and the availability of affordable and user friendly
          effective systems are established.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          a
          market size of this magnitude, just a small percentage of market penetration
          can
          translate to significant market potential for ALRT products. The respiratory
          market potential alone includes more than 16 million people with COPD,
          4 million
          who use a nebulizer to deliver medication to their lungs 3 to 4 times every
          day.
          Compliance with this is essential for maintaining quality of life and preventing
          rapid deterioration. If ALRT were to establish their nebulizer monitoring
          system
          (the company has the only nebulizer monitoring system in the world) with
          </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>JUST
          1% of the 4 million users of nebulizers the first year revenue would be
          $19
          million with gross profit of approximately $14 million</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
          With
          several other disease conditions having equal or greater potential, this
          level
          of revenue and profit could be achieved in multiple population groups,
          such as
          mental illness, and diabetes and heart disease.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>HEALTH
          INSURANCE INDUSTRY</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Healthcare
          costs in the US account for 15% of the gross domestic product and is expected
          to
          reach 25% by 2020. The insurance industry readily admits that enhanced
          compliance will lead to lower costs of healthcare. Currently there is no
          available system that can assist insurers to assess the degree of compliance
          to
          prescribed medical treatments by their plan members. The ALRT monitoring
          systems
          will provide an affordable means for the insurance provider/payers to improve
          targeted plan members compliance, and monitor their compliance by incorporating
          the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Constant
          Health Companion</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          and
          monitoring system into their program, insurance payors (corporations with
          self
          insured plans, Medicaid and Medicare) will be able to reduce costs of providing
          care by monitoring plan members with disease conditions where noncompliance
          will
          significantly increase healthcare costs.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Additionally,
          insurance payors will be able to base co-pay or plan premiums on the level
          of
          compliance or provide discounts to those who are compliant. The health
          insurance
          payer has the most to benefit in ROI through the incorporation of compliance
          enhancement and monitoring/intervention products and systems. Depending
          on the
          disease condition, the annual savings per targeted patient could range
          from
          several hundred dollars to several thousand dollars.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ASSISTED
          LIVING ORGANIZATIONS</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Companies
          providing assisted care services are often penalized by state regulatory
          boards
          when medication errors or other noncompliance are apparent. The ALRT system
          will
          keep the caregiver compliant and thus reduce errors thereby reducing costly
          penalties from state funded plans. The ROI is significant and the benefits
          achieved are realized by the patients with improved health outcomes, by
          the
          payers with better health and reduction of cost of care, and by the assisted
          living company with caregiver&#8217;s job made easier and reduction in costly
          penalties. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>One
          medium sized national assisted living organization alone could utilize
          nearly
          10,000 ALRT systems which would generate nearly $5 million in 12 month
          revenue
          for ALRT with 75% gross profit margin.</strong></font></div><br>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="left">
            </div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
            </div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right">
            </div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" width="100%">

              <tr>
                <td align="left" valign="top" width="62%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Corporate
                    Profile - ALR Technologies, Inc.</strong></font></div>
                </td>
                <td align="left" valign="top" width="10%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Page
                    5</strong></font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><strong><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Market
          Potential Continued</font></strong></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>COPD</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Nearly
          16
          million people in the US suffer from Chronic Obstructive Pulmonary Disease
          or
          COPD; of these more than 4 million people take medication through nebulizers
          (a
          device which delivers medication with compressed air that breaks the medication
          particle size down and more effectively delivers the medication to the
          lungs).
          The COPD and respiratory care patients consist primarily of patients with
          lung
          failure issues related to bronchitis and emphysema. Many of these patients
          have
          to use nebulizer medications three to four times a day for the rest of
          their
          life. Health insurance providers are spending billions of dollars for case
          managers to look after their patients, and once the case manager has left
          a
          patient&#8217;s home, the patient once again is left on their own to administer their
          medication, many of times which they are non-compliant. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ALRT
          is positioned to dominate the nebulizer market, with the only Nebulizer
          Monitoring System to be available, supported by pending patent protection.
          </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          addition to the COPD patients use of nebulizers, many of the millions of
          people
          who suffer from severe asthma also require the use of the nebulizer and
          many of
          the home care providers who service the COPD population also provide services
          to
          those with severe asthma.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ORGAN
          TRANSPLANT</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There
          have been nearly 300,000 organ transplants over the past 10 years and more
          than
          30,000 new transplants annually. Adherence to treatments in organ transplant
          patients can rapidly affect the life of the patient. The number one reason
          a
          child loses a kidney transplant is because parents forget to give the
          medication. ALRT can assist organ transplant patients in maintaining a
          rigid
          medication schedule. The cost of losing a transplanted organ is significant
          in
          that the health of the recipient is at risk and another transplant becomes
          necessary. The monetary cost can be several hundred thousand dollars per
          case.
          The ROI for the family and the health insurance provider is obvious and
          the
          benefit of a transplant center offering the monitoring system is the added
          value
          of care along with differentiation from other centers. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>A
          pilot with an organ transplant patient commenced in February of 2006 and
          the
          ongoing results have been nearly 100% compliance</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          and
          astatic users have said it has helped make their life much easier. A marketing
          program to all organ transplant programs in the US will begin in late fall
          of
          2006. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>MENTAL
          HEALTH</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There
          are
          currently 44 million mental health patients being treated with medication
          in the
          US alone. The high-price of medical non-compliance of mental health patients
          not
          only affects the patients and their immediate caregivers, mental health
          patients
          suffering from bi-polar and schizophrenia and other panic disorders can
          also
          generate significant cost to society. ALRT has already generated attention
          with
          experts in the mental health industry and commercial pilots are expected
          to
          begin in first quarter of 2007.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>HIV
          / AIDS</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There
          are
          approximately 1 million patients in the US receiving treatment for HIV
          and AIDS.
          Treatment programs often involve complex regimens and adherence is essential
          to
          maintaining the health of the patient by keeping the disease in check.
          The ALRT
          compliance reminder products have already displayed their ability to enhance
          compliance via the Columbia University clinical trial and more recently,
          ALRT
          products have been selected for a major project for HIV patients in Kenya
          that
          is funded by the NIH (National Institute of Health), and sponsored by the
          University of Nairobi and the University of Washington. As the awareness
          of the
          value of the ALRT compliance reminder products become known in this population,
          which exceeds 40 million worldwide, marketing to the many organizations
          that
          provide assistance to this population will be launched.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>OTHER
          MARKETS</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          addition to the company&#8217;s target markets, we believe that there will be
          significant need for the ALRT compliance monitoring system in other disease
          categories which include but are not limited to </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>16
          million patients with diabetes, 20 million patients with Asthma, and millions
          of
          patients with heart disease, congestive heart failure, coronary artery
          disease,
          diabetes, Parkinson&#8217;s disease and Alzheimer&#8217;s disease.</strong></font></div><br>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="left">
            </div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
            </div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right">
            </div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div>
          <table cellpadding="0" cellspacing="0" width="100%">

              <tr>
                <td align="left" valign="top" width="62%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Corporate
                    Profile - ALR Technologies, Inc.</strong></font></div>
                </td>
                <td align="left" valign="top" width="10%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Page
                    6</strong></font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Products
          and Services</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All
          of
          ALRT&#8217;s products are tailored towards disease management and compliance
          monitoring which helps to generate better health outcome to the patient
          and
          lower the overall cost of care to the provider. The products are affordable,
          portable, and easy to use. The patient/user does not require a PC to allow
          monitoring, only a phone jack; making it easy for elderly patients.
</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
          product line consists of Medication Reminder Devices, Compliance Monitoring
          Systems, Monitoring and Intervention Systems, and a Diagnostic Test Monitoring
          System. In addition, diagnostic data monitoring capability has already
          been
          programmed in the ALRT system and will be added to the commercial offering
          in
          the future.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Constant
          Health Companion&#8482; Compliance Reminder and Monitoring System
</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Constant
          Health Companion&#8482;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          (aka
          ALRT500) Compliance Reminder and Monitoring System has been the primary
          development focus of the company, as a result of qualitative research conducted
          in 2000 with leaders in the healthcare industry. The </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Constant
          Health Companion</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          is
          designed to manage the medical and health compliance needs for anyone suffering
          from a chronic condition including HIV/AIDS, diabetes, cystic fibrosis,
          CHF
          (Congestive Heart Failure) COPD, organ transplantation, and mental
          health.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Constant
          Health Companion</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
          not
          only reminds a person to take the necessary health management medications
          or
          other actions at the appropriate time(s) of day but it also displays on
          a LCD
          screen the exact actions to conduct, allows users to access critical data
          such
          as medical clinic names and phone numbers and any precautions from use
          of
          medications. The </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Constant
          Health Companion</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          makes it
          possible for insurance providers, case managers and/or family members of
          elderly
          patients to monitor a patient&#8217;s proper compliance of medication and compliance
          of other disease management activities. The system also has proven beneficial
          as
          a reminder to caregivers in assisted living organizations - to assist the
          caregiver in completing the many tasks as scheduled. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          value
          of monitoring are many; including more timely intervention which can prevent
          deteriorating conditions, ER visits, etc. and prompt case managers to initiate
          additional behavior education and patient training on the necessity of
          adherence
          to their health management treatment regimen. A study conducted by the
          Missouri
          Medicaid Program showed a $3,400 annual reduction in cost of care for each
          diabetic patient using a disease management compliance reminder</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ALRT
          Nebulizer Compliance Monitoring</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ALRT
          is
          the only company that offers a nebulizer monitoring system. This system
          will be
          commercially available along with the Constant Health Companion. The
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Constant
          Health Companion</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          connects
          to a custom port at the nebulizer compressor switch, and can be adapted
          to all
          types of nebulizers at minimal costs. This system monitors the use of the
          nebulizer by:</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div>
          <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td style="width: 63pt;">&#160;</td>
                <td style="width: 18pt;">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
                </td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Recording
                    time of day used </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div>
          <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td style="width: 63pt;">&#160;</td>
                <td style="width: 18pt;">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
                </td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Recording
                    length of time used </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div>
          <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td style="width: 63pt;">&#160;</td>
                <td style="width: 18pt;">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
                </td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Alerting
                    healthcare providers or caretakers when person is noncompliant
                    </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div>
          <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td style="width: 63pt;">&#160;</td>
                <td style="width: 18pt;">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
                </td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Allowing
                    for timely intervention when a patient is
                    noncompliant</font></div>
                </td>
              </tr>

          </table>
        </div>
        <div>
          <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td style="width: 63pt;">&#160;</td>
                <td style="width: 18pt;">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
                </td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Recording
                    nonscheduled nebulizer events which can assist a caregiver in
                    better
                    understanding a patient&#8217;s behavior in using the
                    nebulizer</font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="left">
            </div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
            </div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right">
            </div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" width="100%">

              <tr>
                <td align="left" valign="top" width="62%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Corporate
                    Profile - ALR Technologies, Inc.</strong></font></div>
                </td>
                <td align="left" valign="top" width="10%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Page
                    7</strong></font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><strong><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Products
          and Services Continued</font></strong></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ALRT
          PC200</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ALRT
          PC200</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          is our
          second generation medication reminder system and is currently available
          on the
          market. The </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PC200</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          can be
          customized for each patient&#8217;s need and can be programmed by their healthcare
          provider at the medical clinic or by their disease management provider
          and
          mailed directly to the patient. The </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PC200</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          is a
          stand-alone medical reminder without the attached monitoring system. This
          reminder system is light weight, easily transportable, and gives healthcare
          providers a simple tool to help keep their patients on schedule with the
          medication.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Specialized
          Products</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          addition to our primary products, the company has also developed a successful
          line of specialized products targeting specific healthcare needs, including
          the
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Contact
          Lens Reminder</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
          the
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>48
          Hour Reminder</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
          the
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Weekly
          Reminder</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
          and the
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Monthly
          Reminder</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
          These
          products are designed primarily for pharmaceutical manufacturers and retail
          distributors. Many medications are now offered for weekly administration and
          monthly administered medications are also now available for osteoporosis.
          Patients who are switched from daily to weekly or monthly are thought to
          have
          even higher prevalence of noncompliance.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
          specialized product designed specifically for the veterinary pharmaceutical
          market, the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ALRT
          Pet Reminder</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
          is a
          medication reminder product for pet treatments and medications. By reminding
          the
          pet owner to administer a medication on schedule, the ALRT Pet Reminder
          can help
          optimize a drug's therapeutic benefit to the pet. Nearly 40 million dogs
          and
          cats in the US alone receive heartworm preventatives. The ALRT pet reminder
          has
          been shown to improve pet owner compliance with heartworm preventives by
          25%.
          Missed doses of heartworm preventatives can result in the pet contracting
          this
          potentially deadly disease.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Competition</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Although
          there are now a few companies offering disease management home monitoring
          systems, they are focused on specific population targets and most systems
          lack
          portability. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Also,
          the ALRT system cost to the market is significantly lower than other
          competitors, with the company still generating very healthy
          margins.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          Competitor&#8217;s hardware costs range from $100 to $3,000.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          ALRT
          system is being offered at no cost for the hardware with a 12 month contract
          for
          compliance service. The compliance service fee is $40 per month with continuous
          monitoring, reminders and messaging. The ALRT system, in the future will
          also
          provide similar features offered by a few competitors such as linkage to
          diagnostic or medical equipment to record and transmit diagnostic data
          to
          medical professionals and caregivers.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          ALRT
          system provides many features that these competitors do not, such as compliance
          reminders, compliance with medications, compliance with treatments, compliance
          with use of nebulizers, and reminders to use diagnostic tools. Other competitors
          offer medication management systems that are narrowly targeted to people
          taking
          many different medications and who are at risk of overdosing or taking
          the
          incorrect medication. ALRT also offers a medication management system that
          reminds patients when to take their medication, the type of medication,
          and the
          dosage amount at a significantly lower cost.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
          comparison chart can be found on page 8.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="left">
            </div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
            </div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right">
            </div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div>
          <table cellpadding="0" cellspacing="0" width="100%">

              <tr>
                <td align="left" valign="top" width="62%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Corporate
                    Profile - ALR Technologies, Inc.</strong></font></div>
                </td>
                <td align="left" valign="top" width="10%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Page
                    8</strong></font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Competition
          Continued</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Below
          is
          a comparison of the product features of current medication compliance monitoring
          systems on the market. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <div align="left">
            <table border="1" bordercolor="black" cellpadding="2" cellspacing="0" width="100%">

                <tr bgcolor="#cceeff">
                  <td valign="middle" width="14%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Company</font></div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Compliance
                      Reminders</font></div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Monitoring
                      Compliance of Meds and Treatments</font></div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Monitoring
                      Compliance of Diagnostic Testing</font></div>
                  </td>
                  <td valign="middle" width="8%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Monitoring
                      Diagnostic Data Recorded</font></div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Medication
                      Management System</font></div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Auto
                      Medication Delivery System</font></div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Monitoring
                      Use of Nebulizer</font></div>
                  </td>
                  <td valign="middle" width="8%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Lowest
                      Cost</font></div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Full
                      Range of Reminder Scheduling</font></div>
                  </td>
                </tr>
                <tr bgcolor="#ffcc99">
                  <td align="left" valign="middle" width="14%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ALR
                      Technologies</font></div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>X</strong></font></div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>X</strong></font></div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>X</strong></font></div>
                  </td>
                  <td valign="middle" width="8%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>in
                      2007</strong></font></div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>X</strong></font></div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>X</strong></font></div>
                  </td>
                  <td valign="middle" width="8%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>X</strong></font></div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>X</strong></font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="middle" width="14%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cybernet</font></div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>X</strong></font></div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>X</strong></font></div>
                  </td>
                  <td valign="middle" width="8%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>X</strong></font></div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  </td>
                  <td valign="middle" width="8%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="middle" width="14%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Health
                      Buddy</font></div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>X</strong></font></div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>X</strong></font></div>
                  </td>
                  <td valign="middle" width="8%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>X</strong></font></div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;X</strong></font></div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  </td>
                  <td valign="middle" width="8%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="middle" width="14%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">HomMed</font></div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>X</strong></font></div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>X</strong></font></div>
                  </td>
                  <td valign="middle" width="8%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>X</strong></font></div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  </td>
                  <td valign="middle" width="8%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="middle" width="14%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Informedix</font></div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>X</strong></font></div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>X</strong></font></div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>X</strong></font></div>
                  </td>
                  <td valign="middle" width="8%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>X</strong></font></div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>X</strong></font></div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>X</strong></font></div>
                  </td>
                  <td valign="middle" width="10%">&#160;</td>
                  <td valign="middle" width="8%">&#160;</td>
                  <td valign="middle" width="10%">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="middle" width="14%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Nex
                      Dose</font></div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>X</strong></font></div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>X</strong></font></div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  </td>
                  <td valign="middle" width="8%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>X</strong></font></div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  </td>
                  <td valign="middle" width="8%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  </td>
                  <td valign="middle" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Growth
          Strategy</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          company&#8217;s goals are to make the ALRT compliance monitoring systems a &#8216;standard
          operating procedure&#8217; (SOP) by health insurance payers and their contracted
          disease and case management companies.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Progress
          and results to date reveal significant recognition of need within the health
          insurance payer industry, the assisted living organizations and the special
          needs markets such as COPD, organ transplantation, diabetes and heart disease.
          With the aging population and increasing number of elderly due to the aging
          of
          the &#8220;boomer population&#8221; the need for the ALRT system will continue to achieve
          healthy growth as the boomers age. The increasing availability of disease
          treatment and prevention remedies creates an ever increasing need to assist
          the
          patient with the actions they require to complete on repetitive basis.
          </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>The
          ALRT system provides ongoing support and continuing oversight of the patient
          where current health management practices fall short</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
          </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ALR
          Technologies is currently raising additional capital, which will help the
          company to speed up entry into the marketplace with targeted market promotions.
          Besides being used for sales and marketing, proceeds will be applied to
          manufacturing and inventory build-up, research and development and debt
          relief.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="left">
            </div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
            </div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right">
            </div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ALR
          Technologies, Inc.</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Important
          disclaimer</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
          corporate profile is presented as a brief company overview for the information
          for investors, analysts and other parties with an interest in the Company.
          ALR
          Technologies, Inc.&#8217;s management hopes that this corporate profile encourage
          analysts and investors to investigate more about the Company through its
          Securities and Exchange Commission (SEC) filings, press releases and other
          public materials. This corporate profile does not constitute an offer to
          sell or
          a solicitation of an offer to buy any securities of the Company. This corporate
          profile contains forward-looking statements, including, in particular,
          statements about ALR Technologies plans, strategies and prospects. These
          statements are based on the Company&#8217;s current assumptions, expectations and
          projections about future events, which are subject to a wide range of business
          risks. The Company encourages investors to review the information regarding
          the
          risks inherent to ALR Technologies and its industry, as described in its
          Annual
          Report on Form 10-K, as amended by Form 10-K/A, for the year ended December
          31,
          2004, copies of which are available free of charge over the Internet at
          the
          SEC&#8217;s website at http://www.sec.gov and at the Company&#8217;s website at
          www.alrt.com. This corporate profile does not purport to be all-inclusive
          or to
          contain all of the information that a reader may desire as to the structure
          or
          the affairs of the Company. Although the Company believes that the assumptions
          reflected in these forward-looking statements are reasonable, the Company
          can
          give no assurance that these assumptions will prove to be correct or that
          financial or market forecasts, savings or other benefits anticipated in
          the
          forward-looking statements will be achieved. Forward-looking statements
          are not
          guarantees of future performance and actual results may differ materially
          from
          those projected. The information contained in this corporate profile is
          only
          current as of October 1, 2006 and the Company undertakes no obligation
          to update
          this corporate profile. In the interest of full disclosure, we call the
          reader&#8217;s
          attention to the fact that the Mercom Capital Group, llc is an investor
          relations firm hired by the Company for a monthly fee of $7,500, and has
          earned
          2,000,000 stock options of the ALRT stock. The stock options can be exercised
          at
          a price of $.25 per share. Mercom Capital Group, llc is not a registered
          financial advisor. Penny stocks are highly speculative and are unsuitable
          for
          all but very aggressive investors. Always consult a registered financial
          advisor
          before making any decisions. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>
          <div align="left">
            <table cellpadding="0" cellspacing="0" width="100%">

                <tr>
                  <td align="left" valign="top" width="48%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Corporate
                      Headquarters</strong></font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ALR
                      Technologies, Inc.</strong></font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">tel:
                      1.336.722.2254</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">e-mail:
                      alrt@mercomcapital.com</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">web
                      site: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>www.alrt.com</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
                  </td>
                  <td align="left" valign="top" width="4%">&#160;</td>
                  <td align="left" valign="top" width="48%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Investor
                      Relations Contact:</strong></font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Mercom
                      Capital Group, llc</strong></font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">tel:
                      1.512.828.6645</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">e-mail:
                      alrt@mercomcapital.com</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">web
                      site: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>www.mercomcapital.com</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div><br></div>
          <div>
            <hr style="COLOR: black" align="left" noshade size="2" width="100%">
          </div>
        </div>
      </div>
    </div>
  </body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>LOGO
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"``K`)0#`2(``A$!`Q$!_\0`
M'P```0,$`P$`````````````"@@)"P`!`P<"!`8%_\0`0!```00!`P($`@<$
M"`8#`````0(#!`4&!P@1$B$`"1,Q"A05%A@B,D%1%QI"<2,H.%AA@:'1)"8I
MD<'QTN'P_\0`'0$``00#`0$`````````````!P4&"`D!`P0``O_$`#D1``$$
M`0,#`P("!P<%``````,!`@0%!@<1$@@3(0`4,0E!%2,6%R(R46%Q&25#1%*!
MDH6AL='A_]H`#`,!``(1`Q$`/P`_1QSH*>1R#U<GD#CI'/`'<J)')X'Y)4>>
M>`?DVN05%%&3-N[*NIX*I$:&)MI/C5\3YN:XAB#%]>8ME!DS)*T1HT<'UWGG
M66VVU+=2D:QW#ZWX/MOT9U"UOU&G"#B>G6.3KZP*2/FY[[00Q6TE:V>/F+.]
MLWH=17Q@07IDQD?=`*T-1Z;9Q=X5MBRWS7=[:7;S4P8/;Y_HMI+/7(9PK0K"
M<EXKM,L*P6C<:>;8U`U,3/Q_ZUZBS(#F6/Q;^+3=42OKI[-DB6-T&`=(R(UQ
M61)%C+(]W&/`K8NW>F27-:YW)[N3(L=J(Z2X1U1XQ@*1I7P;2BWR^D+DKW'C
MUDC**G`<6@PHON[G-]0KUG=K,3H8Y"`CM007!E7UQ(/[>BBRZ]5C6$^RK:R<
MZAK9N4T2VZX]"R7674"FPJ);RFZ_'*N6)MCEF7VKST:.Q387A=+$LLLR^Y>D
M3(K"*K'::QG)<?;]5AM"BL8:O7^@1@USJAJ/CUYH-IU2Q3->R37&PQ#"%O0%
MK;3&L7JQK)KB7CT62%I:1`S0XODZ)SC$!['&WW2&V:O+-T@R/<"]=>;!O?L(
MEOG>31;V=H93W@2W@^A.CM";4OY)CL.<Z_&KVY;8M7*NQ?"I$*D:D9"_)?L\
MEL)B!Q?-)\R#/-]&M.15U)D-K7[<,*O9E9I9A+,F7%K+R'6/R8;&H62UQ6CY
MK(LE;ZYS34Y)DT55*9IV"VIMZ5*8=WJ*^EI@WLF*@TM5<N/T[D5LR1%1K7)8
M69W<V1Q/&\94B1QJ5BO$-\A7/)[>8VDO0]%U5U.M=(:"]-,)ITR,FM^J:<C8
MOCN0%D/$3`].ZN.V.^[MXAX\^MEY!?3EA3#UUE*ATL*+`C%NR1=9?B,]E>GU
MZ[0Z<XGJQK5\I+>CR\DH:BKQ/$76F%OLK>J9V56$6_L2J0QT,%[&8$*2TXB0
MQ/<;(Y36]\3YIPEUY+&T7-W&4+=#+CVK-"TZM`5TL>LRSA4I#+SA(]5M#\AM
MD'E#[_"ND/P)Z2""!^2CP!V2GJ4I92`5)Z4<K*P[][I0E'24A#[_`)9ODO#?
MIH9>ZVY=J_D&D-6SG=GA^)P8&"0\G:R:'25M>JVNT2IF3T*V(S%O+FT_HL,+
M0N57RU&0"@-(%]9J)J7E%DL&D+#24]I#MB1XE<,(Q,XH[<UEW'<45R-:XLAC
MG$>Q$15<UBV%9YT1]`_3Y@3<OU<K\E)11)E?3GR*WR;-95E,LYZN2,QM7@Y8
M;2%,@S&>R#3(P,<!CO:,0GD1R']Y\T\YX^R)F(^\D'JU>I`0.D]:BD8&HD)<
M'0GI!ZQ]\]'9)K]Y]T]`[[0<T!Z.K@ZN4G///'3P<#"CRG[P(23[@I'N17MP
M6CF0[>M<-5=$<I#WTSI=G628?(D.,&&JSBT]C)CU-RTVEQU*8E]4H@W,3I>>
M2Y"G1W$N+2M+BG+=)?*SQ_4KRSL^W_OZR7%3<X5`SV>UIHSA<.573U89?BD0
MVK)W,C8D1OI``R2L4;_RO5Z)1)X#OC3!SW5"QESH,6<)\JMC2IDT1*^G"\$>
M"K6RW.[H1M<X3G(WML5Q7+X:QRHOI8ROHV^GQA./X;E618?.CT&?W^,8SB5C
M#S#5.S#<7&9B<;&P#2MNYA(\>P")Y&SI31PAH[E(D@:X:>G=/WGW3SM_5$S+
M@\]QJ]1GW`*!T_40+Y4>H*'3]SIY///BOWGW3WD`[0<T!/3V.KE'U!)Z@LJ2
MG!%=)0I/`!(*@0KM[>`_^Y!0"0%`@_>4>Z@4K/XA^)(4./8%0/\`#P2$MG_D
MLZ1[AME>G6\34_=H[HC09BC,WL@CV^$X^YB^*HQK53*]-8;TO*[?-:)@(MY-
M%7.H5*C1$LR9[4!"GUH$A_-)G>J&1230ZBPCR#1XKYQD+$I(K611$$$A%+)$
M$2-80P]TW5Z(Y5VXM<YO/JUT>_3XT/H:G)=2,)NZBIO,D@XC4D@9#J[D4J=D
M5E#L)\&M!6X]:V5BXDJ-5SE`1`.&\H61U5#R([2+N_>?-/O[H69?A!'.KU(G
ME74!T]\#!X`//4D*[\)('5SXO^\^:>\D#:'F?;J)'[7:/E(`/0%)&"$I6I0X
M4@_A"DJ!5R0$W5/D$:":LLRX&W3S'--M3,J@QI$AVGBX[BN0-K0PVV0Y(9Q'
M4^SL8D0N2&F9$TPWVXRRDI0XM*FU)/V[^4[I#D<W6O!]WV\;!=J6KNC6K<_3
MA_!KQ_"IJ<DIX^,X[D%;G%-,R'-L2ES*"]1?)54RFZU:),2,AYYYF2X_`@+)
M;S64)8PRR83&RU(T$A?T96&]X1=X@W34<L49.VU[FC(1A'HU5&UZ-5?0MK])
M/I:VM=?SX&/95(/BPZZ1>T/#J##E<.)9S&P(M@S%3H._FUONGC#)GP*^5$@/
M/']\>-[F.A'0/WGS3WD#[(69]^D\_M<I>`D@=9Y^H?'*%'C@D=20I0(Z>/&P
M,1^)GVVV,ZM8S7;SK/B\&3TBRL:&XPO+D5RE\<+8CR[#$W;)A'(]1Q!CN@`A
MN.XOA"DOY#\/UM<Q'"*+4K+/,4J<9T\RAZN:QO.KW#L)J\3OG;BNE654S37\
MW4]BKGO6,*'-G0FXTIU<EB+)#2%AI:PR)OWVP:-;5M5L;P;1/<3CVY3&[K"8
MF36698VC'Q#J;E^ZNJY[''E8]DF4PA)CQJZ+8="YK,AAJ<TGT&^HK<UVV4ZM
M8Z#WEM*K6!:HMQN7'3N>AE_*?V()%EO$]45.8F(Q$\]QJ;/10TXZ>OIK:WW"
MXKIOC6=2+<@;/>8UNM]1#C$JVJV>-UQE0&X^&?$<[=(4HCRO.-`J!^[V>C_=
MM^^#;KN]PBPS';GGE9J%+JHWK6V$N._5K.:5_J*!%O,;R%,&PK$NN)6Q$M76
MET,V0DMQ;5U*5N(SU6\_1A&HU7H[J0]D>A&K.0?,JQ7!=:JJ/B3N;-1I`C+7
M@.:0K&\TPSZ1ZCD?KJ\,SJ]N8GS4=N?6Q'W4,JC<-$M<=5-N>I6-ZMZ.YC:8
M7G.+S&I4&T@/J^7F,I<0N157L%8=CWU+9!"(]C3V+<J)-;Z4+84I*2@[C2.\
MV_>=AL(K7M0Z:%$R#J<ILI11*<9O]%];:2L95]/XA.D%<J)RU8Q+RI]5R1$L
MJ2U556?S93.`>N':C3<M`:*(<.-D4(+CM@%5Z0+<#%9W%";93P9#5>C/+Y0V
MHJE0)6-+V8G=4/0SBG39;U>26,_*K[0K*;<=*;+ZWVQ\YTPMY0GK"6[JU"*B
MRRA(B$./VX\>L;`@'5C;"KDNB'LW9E9;C:+]O%5WE0WDST-5@QCSUE%9O)%<
MCLY81ZEQQ,^1`;4"AR8Q'<CMK!2XXA0(&D=6=T.!:+7)JLWILQ9C&-3.LWM9
M65EE3R)60UF>6-)5-^E=)M46=FYIW>541J15L1W+>33PS)2FQ;>2R;Y>^K]S
MN)F:U>6-ON^<MM>MMTF=^SK4IJ=85&I<B@QN8S`8R[&\VBJ^EJG-,/,S&[O'
M,KK[!%E<8_<P5V*)B(LYV<O79QN1U%:UIU1V([I7F+?7S1BO:RK3K5!V/"C#
M<)H9)F+CXUJ*[!CM-0H6<5S$B-`SB)7,-UYNESWH[#:HTQ*W?"RAMH&"4"^Q
M99'-$C%.%2K&LX[2I(IK`*/8HIK'!(X!!E>&6T3VL[;GQT-&+*NGL^G5KF,*
MW&F9R,&IJ[)[6KJ;)*L60Z=9"ZN?0:JX)>)'FLNL><.PA#NX!JWWN/.L0&,.
MTB1;B13.;TEU$OZ:IO8*7?D;JM@VT+U4I2[\I8Q6I<;U4!:DH=]%Y'6E*W$)
M5R$N+'"C7CMMMM!"0E"4H2.E"0A(2$I)`"0.D!(X/2`D#IX/'?DUX=W)R;(O
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M`YE%+01)41N2XQE%'/,9Z/+:2^,\H@GD%SB"-'^\N\7AEK-O\T&L2<.=!$NZ
M<R,=(&]1?/&<CT3;DJ6$]/V44597](676+HGZ,:3]0V5U6H*NXJM!9:A/PZ;
MB.4VPU1_"ME1Z68.-/43T"7#IH44A5CB]>IW:6\[1CR.K08&`E4/:+H[A$-Z
MC6&F45&<5&"X9?3HCCJ8:A#%+D-C,+Q0Q,6P7%,I,M:&5@*#]![=(Z>X(*`5
M);(X)20&4MH"F_N<("`5*;6M1X^Q#.</\QCRH;C;M.LF8>H..Z-6>V[4*ML7
MU-66-Y-28\_2X%E\^+$:$H0YJ:ZDR)M7RO!GP+>K4P^Y!?8=!PU+TXS'1_4'
M,M+L_I95!FN!Y+9XKDU3*9<95$N*N6Y%D%H%EKUXTH-B7726F2;*`['L&?4B
M28[I$>J[7S@XA=Q=WU4N@!&CJU%5@3C<\Q@KOY&5&D&US7HURH'BJ;B<C+,/
MIRD#BEGU-Z49$Q(FI6/ZT6^0W092HVPMJ&YCQ853:QVN_,FUSY-=*F`E"4H7
MBO(1VNXSP.+Y6NK+"ZL:^GJ(;]A;6LZ'6UD"(VMZ9-L)LAN/"APV6PI;LJ5*
M<988;"%=:W`"`GD@T_=UK/8^5;H!Y;VW?2N%=37,6SO#LLUA7CM;.FN7N`X4
M69>JC<]F,PIYMW.<GRRQLXRY:TE/T5*1TOJCE"1V?*&Q+2&_WR:8Y7KIG>"X
M!IQH^Q9ZMS)^H&1TV,U=MD6+O0XF%4\.;=28L9^Q:R^UI,@<KO549%7261?9
M5':>4T\-N]^(8U2TOW%:GZ>[><$T"U(TGP^YC4>.9SD<3,KJ5DDJ+6PE7%A$
MM,;SJFIY=2NZ<L8M4Y&A,&1&#+[;DMMT/N\^$&K:+'+>YG6_X1,M9<>HKS@C
M?B$P`8I!3Y9?9C.`J"DN$V,0CB,X*)$:G-R<U?JS@9YJWKKI=I=B6EZZFXKI
MSCF1ZDYQ2W5^F&8G;6N1PY.&8S!+DLVIMHGXSCPI<V\'!!$DF+'GHJM"@3%:
MGWXC7;U6XMKWI+N;Q2(5T.OF%?0N2641DNUTK,L"CUT2ML3+:1QZMU@UC01X
MS;B.7F<8DR4.N%3J&%7;63S\.)KH$J0KJH-<R#ST\!6>\IYY'XBE04`>_)">
M?=0Q;E-WVAGF;>4GD%YJCGFC&F>Z#!K.VSJLTT^LT.EDMY?I_;6S+4+%JG);
M63D<EC.-,YK[$!A;TLJOYZ8H<DH@I6OZGEOYIM<U#\G^YVJ:O;GM+=%+W4:?
MJWC]JG(\NQ2#D^/P+K,79D.R^K5W=5+[B7XC3#T8.N1FW6W>I#W*5`.P`*]V
M;7=C6S(:P\IPNRF1'O/'BM29.'$$4!T*1&QCEE(IR#*K7-4R;.5K2.]1PLK7
M.872;H[AF?8SE`<IZ<.K7!,4RD,>FM[TQ,2PR7>V%9=U*5L$Q+FCA4!65$*?
M6C+'F)4M]LB*<#/0@H/8*(4`>D\\'I2%A7`4>QZN3P4I"@.Q*AU`>#<=EFA$
M/<U\/_I]H58Z@4FE4//*W4:')S[)8C$VDQY%/O`S+)/7GQ9-I2MNHEN4[=:Q
MS:1>F3-CN!2U`,.-R'R=_+=Y!'FQ:;*`X!)D:5*)XZ0@+5^T<$A1`"DH*%K`
M/!_-.UIFL^W_`!KX?;+=O%=K9IO;:D4SVH%+688,PQM.;7$./O=O;VJL$8O'
MLG9ZA9XNB+D;2&F76OHR0'DO+3]Y3?P^EDXM)R(UZRN)&EX5?B$`-Q#*DQXR
M5CG0E-"D%>`DA'J,;^37HKG.$C^T[8R]46JE)U$8_H=3Z-R\W@WU!U8Z)S9%
MW9:7Y=7/Q9EE"SN-#RE(&6T-9`MXE',"*9+"17P!N&&/:&"&6-Y52>73Y+]5
MM0W&8KN=K]V=#K2-.ZK,X\'#=.\3C5[&02<KQ#(,.6S<7O[0KMA#+#5L[/C0
MW(01*NXT`KG0$05*?&D\SG6VRW";Z-P&I-I@^1Z<//97"Q1C#,QA)K,LIH.`
M4%5@\)G)ZYIQUB!>2XF/M3K&!'D2VX3LSY5-C8I:3*<4-Y'^M^):'[^<+N-0
MLQJ,&PC)<&U(Q6\R+)\DA8WC-:ZO&9605CMQ/M),>O6B;<8]'@P$..>JY93X
M;K#0(6$ZF\V^SP_(O,#W`YG@&78UGF&YM:XQE5%D^(7E1D=)/C3<+Q^/+;8L
MJ61*C%ROM(L^!*8=>2_&>CE#K2>H.NIE[,J9NGL!*6"RFB#RHJ3*9)A9[B2E
MK$0<]"2D62C&@1(^S-@<W.<J]U.*$'1[#M1<2ZV,Q;JOE$O5:YE].M0F):GO
MQ&!A$2NH@Y^1;#"/PK'E+C\J<Z>U;@LJ1(2Z$",UHPLKGDXO*>98G_H+>7T1
MP"+W;8GVY';0;58=@2>W<\`E1`)`5[$"E@=R?U"22>.HDCJ')'`/2DI0/N@\
M)!))/8E_S"-=M&,R\E38UI7B.J>`Y+J1BM]H"YDN"TF54]GEE"W2:*ZF5=J[
M;4,*6_90&8-G.A09+\F.TPP_+CI=<1ZJ?`T*>>`>/<)/([I/W4\!*_PKX3T]
M:D%387U-I6OH*O"9J.8)[JO>$HS-3'*1JO&]A$:]D,*.8KFJJ(]CG/:YBJCV
M_NJB(B(A%Z(*ZQJ]+\WCV=?,K3EUUUAF"!.B&A&)%E94<L24P4@8B/!("_N`
M.C5843D>QSF*B^K*_(=_?D$#GC@$'@^X5Z:E]''"NKNE2%`*!4WPQ>87R,KW
M9Z?_`/$NXS*Q[3',@LA9A5M[`M,KI'@@I1T-3+N!9</D*3ZZ,?0I+:RPHI%:
M)XX['IY'6>0`D`]045**4IZ2`HDGGI"^`>3P;M\/AM=N=`=K6H6X34F(WC%C
MN&L:6_J47"5USU;I3I[#OVZ.^L%3D,*K6+VRO\HN6PM+;;]"FEMRZ['F1RWU
M:2PY,C-JPX$<T4`4^5,,C5XLC+#?&1KW+LU4*8[!HBKQ1-W(B.1R^FK]2G)<
M?I.DK/:BX?'+8YA8XK08M`>Y/<R[QF35%TY8C452(2!64\ZR5XVJJ^W8![5;
M(;ZT/JS<2,$^)&T@DXU6<+SG`\?I\G;A,K2;&/>:09=3RK&=Z96'EU<6IK)Z
MW"I/3&I65.GJ80YX5_O=?5A/F\>5YFF.O--9%FU3JUICE$)GI^9GX283TB/\
MYT.+=<@0IN4W%@@*:4TW*8<<2XHH_HDH>7]]+;]_-EU\\P6/5R8VA>CM;::>
MZ4W5A%]%N[L7,?&$T?R#BDLA;_U2<R7+[@)+CE1]8:.%(2MR07E*UT5A66^C
MS0K_`'<5D1$C;-LXQ;(M#]$<N"4O5>J6JU@;&%G^4XW-0I3-G0TK]I?5;%S7
MK>K9C5?0/Q'2Y(D)BERLY3X<I8B/5,BU);:4Z-8K=J^ML(,F=9-V\L`HH$EJ
ME7BBD,-B?FR6M)6QGJQ\2RW&FY(R.!VAG00+3G59D@S",=G.=X5EU!B>GDI7
M[,D726&84QVP1N?)#&KK2:C$C4DD@7S>GDD@HXY_BY!`X'`X(]N./_KV%>+#
MK``2%D?JD\CWY'XR%>W''//;@\^*\&18Z.7DJN155/A6[;?LHFR*[PFWPG]$
M^_FIQ2-1RIQ5WE/VG*NZ_N^5V3_[M\^5]9UHZQQSQV([CD=^/?N#[<\<$=SR
M>>!X2C;[4L>J-6;7771?);#1C4O+!$:U+115D*WT[U<8ANI5&D:D:?2G(<2P
MR6`TJ0S4YMCMKC&7QFY#D6=<VE855RU8^+'\A^1/!_[$_P#CQ\2(D>5V^^)'
MJ$B&"_=S""*U%1"#(Q6D&[BJM56N3DU5:[=JJGIQ4>27>.$G/IIY(C+2"^MM
M8CA@E5]M7O(PZP;6LF"D5]G%;($"6($Z-(&"9'C3`M'*C`*-J+4SR^<LPC<*
MYO#V4YMCFD>M%^RRUJ_I1E,2<C0O7YE4I,BS.4_0K4ZXPS)927'78V6TU/?K
MC6:&+-509TNWFV6@]\?E:XUYCE4-1+S`K?:WNKH:AFG3DTV?BV;X#J!`K"MF
M-7WL_";6;/MZ=A2VF*;([*NQ3-XE64-2,:EQXJ(D!]%PGU6D\]CUD@=N?OI'
M?C_#MXQ*)"FP.`"E2B.!^(J;05>W912XL$CN0H\GVX;\K#J.:&5`-%1:^T,\
MTBNWVA^\<,JNF@8J.)"EN1"*\L)\=I"/4AAE*]Y%+^.]36K6)W&,9147S19G
MA=:&EH,U]OMDH\7CJWM8G<R&%;`R_'1L&@00,OKKLL&(T,&MEP8@`"%'8ZT>
M3;YB6BL^0S+V\Y)J55M.OHAY%HX]&U*B6*&DO=$N/2XZI68Q/62T$M-6N,5L
MP-.)*XQ6TZ2G4;!-]7?HV7[L3R%H'&W?5PD(Y('J`8@4\]0*NQY/2V2`4CJD
MVV^_63[_`'D\^Q(#BDCGCW/3VY]R/<^.8/'MV_D`/;^7@<'T,H"E(2-;6<<:
MN:Y1D9%D.;NU'-:PJ#"Y48CE:U7HYW%5;OONY9X4GU?-8HD"*&\TST\N+!HV
M-=/@FR&E&=K41Z/)"=8VC!F<JM<3LE:!SVHK`":C&CC(OL![Z^?[%N[!("2E
M*?L[:N`)2I96I+9^J'(2>2#P0H`_B'``N-@F^ODG[%^Z[N2?[.VK@/<DGDC$
M.5%2BI:B?=:E$<`@"3@2.KGGOQ[=S^?_`*\<NA/Z?ZG_`'\:$T)J$7=+VQW3
M?R@(R+YX[[;?&_'XW^/'POA8_M@]2_&^C^$+LB(BK>WKE1$1J;(JC5=D1J(B
M;[>/CROJ,=.P3?5_<NW7'W!!V[ZNE*DD%*D+'U1'4A0)"D\@GL01QWL-@F^L
M<?U,-V!(!'4=N^K@5W:#1)4C$$*"BGD$H4D*1PE:5*`7XDX^A/Z?ZG_?Q?I`
M]N1_F?\`?QG]1=5X_OZR\??LQU_T;[_Q_=3YW_[JB87ZP6I2[;Z/X1LBHNWX
M[>[;[M7RG;V7RU/E/.WGY7U&-_8#WU\@#99NOZ1RD)&W?5XI2GGN!_RD0#T@
M!)()'`)"RD>*^P'OKY'.R[=@"/<_9UU:!4>5'GJ^IW)!4HJ6/PE?"@E*BHJD
MX5\CC@GO_B?_`-^?BDCJYY[\>W<_G_Z\>_454[)O>V*^=U18T7;?]GS_`%\+
M]M_Y[^?7E^L#J4OSH]@Z_P#7+W[[;_X7QX1-OA4:U/A$1(Q\;`]]0X3]BW=<
MH'A)YV[ZO<*Z!ZP+@3B!!)4RD`A(Y4EI(X_B]IA'EC^8/G]FU4T6SW7FOEO.
M(:#V;X!<::5P4M*5!;MQJ(SB]0RURO\`I'79S;;2BHO*;ZT!4E4L`$`#W"N?
MS]BG\SW'^7O^?C$K]/R#;BA_,`$$_KQSV!Y'C+="J5%17W=DX;$Y.8P,5CE:
MU/*,>K7HURIRV<K')N[=6K\>M$KZP&JQ(QF0M)L`!*<W:.:7:9'-CA*JHUKR
M112()"L1%5%8.5&<Y/'<1$1/0I>P[X?1_";NEU?WMV-1DKU`IFZJ-O>$K-_"
MFV<1YM^''U`R5*&X-O&:?:"9.+XXF13S7?0=G96]6(E1'7==R&WG<SO/KJ_1
MB1=-;1=J8+,/.ZC&K>IR#7K52CKE(8CX6U]4Y,S3S3#`GXK70\(&4YE9VK1B
M1+*KA5\>936#GB^WJ*[<I`"20#QW:/L01R"20?<$DCCQS4`%<CW)0/<^W2#[
M>WN2?YDGW[^"'58-C]56K60`G#!F\%GHAE239+P8Y&SI3.)W!5BM8H(Y(PE:
MI!.8\)'C=!_.>K[674S/HNHN6V51:930=QN%.D5`S4>GSRD5RR<1QJ0>11-L
M6D9W&6^00+ZV'(!!G#FLG08<B.C\[,L$K](,<VW:>W%II!MWJ*,45_@6FC*:
M#)\XKGF51[2LO]1EO2KV)6Y(PI:,KE434#,+U3TA:\RBLRWV'5-X1@.'Z;8E
MC^!X#CM1B.&XK61:;'<:HH+5?45%9#3T,Q(<1D)0A!Y4MU:NMV0\MQ^0MUYQ
MQQ?J&"25\_HC\ASWZO<^Y]A[\\#L/'8\.8-?#B$5\>.(3T`.,QS&[=J*)$[<
M4'V!&9LBM`%&"Y)S5BO57*"KO,<IR*,L2]NYUD`MI-OY3)!5>MA?6:N?/O;4
MO%IK:ZEH]PS6MF278*%5C))]NB#]80VH?Q@_S2?_`)>*\9O%>.I4W7==_P#D
?J)]OLB[)\?'_`+7TV/\`=W_-WVV_G_+_`,_Q7U__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>chart.jpg
<DESCRIPTION>CHART
<TEXT>
begin 644 chart.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`!P`,L#`2(``A$!`Q$!_\0`
M'``!``,``P$!``````````````<("04&"@0#_\0`-A```@("`@$"`0H&`@(#
M````!08$!P,(``(!"144$Q87&%57EYC7V!(V.'>XU7AY$;<*M;G_Q``<`0$`
M`04!`0``````````````!0(#!`8(`0?_Q``W$0`"`@(!`P($`@8+`0`````!
M`@,$``41!A(A$T$'%"(Q(U$R87%S@?`5,S0V0D-R=J&SM>'_V@`,`P$``A$#
M$0`_`/?QQQQQC''''&,<<<<8QQQQQC''''&,X5B9%U0#S&)L/A5=?'_#_'G6
M(K!"AX/Q<K!!B_&$R6>-"C?$S9,:''^6S]/EI4C!'Q_Q9LN/IVYKD1W$!*F`
M@`@`$LY$\JL^(\(F(Q=+&O`#/(`,*Q++*L*RH<FMF";F%L9`$4$.^8>.P+1H
MZ?#3.[B$68$ZG0FF+U4R3W@70!I?RG?;IX/.@V5(&U@(M/-452@$QL$K9M\Q
M&(]+5*Y+EJBF6O2:W,PFDHS5H"!65E+Z8$%5^QFBA`D.%8,<HI/A#8V6:-&X
MI!"5@AX,A$R1BAP\#'FD9,>/O-*EIT$6-B]>WG/.(S(L&+CRR9&'%W$B0X,.
M(&#$^$*$BH4HD4*$I6"".&CH.#)*G3R$Z5DQ1H<*'&Q99$J5(RX\$?!CR9LV
M3ICZ=NWBG397UUG>S3%BXC7<UDL]+8L+$?;!YRMB0<%L:BN]>S%FM?)N!/'?
M1?4H4@-L..-GT[*;CT.1CQX+=-&1+VKR%*3K"(T2JA#<>::LE<9ZT<6W'*-0
MI>=Q/US;BS8#G(59TLCU$PH3UD6R\NM`I.2HA`(XVLKI4=6XL?*$K;&32M.Z
M6Z8.LI.;EALC=H4<EUD+1\4=P=ATLB9#Q9_7,+ERL?F%)++C"+CRO';Y#,1!
M&8./)VDBYV+!V?E+?F)9):V6RXPU>&JU*EOJVC($3P\@<<YE#A+-:15S3K-5
MU9DFH1XU`J@KXB+O<Q-?90U=QKDY).B7KI+6U;I9FOK_`&&U6K/#$6>IH!4U
MA@RL<>Z6'Q%(!^NQ%-D)YU=)8[^-3POO52A;+,X!BM6].2DH.;F5W![M\O(-
ME9&,T&XY!.OB21KY1:ULF(9Q>3K;EN%X&9G<,[IW.`&%^-G5@\*(3&MJ(Q(4
M];("NI*&7[AC<EIP,9PV)S%C,T^<G;C&....,8XXXXQCCCCC&....,8YA:$6
M/4(;2WJZPF5)M2`KS]U==<>MXA4V/L7!8=BZN+*?K46V$3-;V!I+ZY5U2..S
M*CQNV!#=JQLQ*S)^S-E6NDN-I93=&P+-/[I<<?S_`#_\QGGNN2L_4`+4U4U?
MUI3V]RS>H19N0C5FQ2UN%5Q!8I$:WV_8WU>Z<V[K*PM],@G9EK1*;CU4`V2N
M,FH[4L/05E<S.O#L6N<V->T72K2=5N1*JJU8[2D7"D"IEGFC&O53;47KGNZ[
M4ROO-:5U#D+EOWM$N_;O.P=F"\A]M-ZX2BVK8<A3J]M35WJ'&R5[LIC[S\<8
MRMZC9-\.@J68%U-4<>-#9W=3RXR%[N6+/V(H3H?13&;'UCZ[2L?F%)++DZ0-
MR=LO7/F'98N:5&AR>^:)@[/[[L3]UE+?CX\_MMXH/^1CO]Z=DO\`(FT^33QC
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MCB6&/$HRO-6CDD;N=N_N/`'V=NT<*`!]/;QX\C@GGGDPM[[L3]UE+?CX\_MM
MX]]V)^ZREOQ\>?VV\FGCGSO,O(6]]V)^ZREOQ\>?VV\>^[$_=92WX^//[;>3
M3QQC(6]]V)^ZREOQ\>?VV\>^[$_=92WX^//[;>33QQC(6]]V)^ZREOQ\>?VV
M\>^[$_=92WX^//[;>33QQC(6]]V)^ZREOQ\>?VV\>^[$_=92WX^//[;>33QQ
MC(6]]V)^ZREOQ\>?VV\>^[$_=92WX^//[;>33QQC(6]]V)^ZREOQ\>?VV\YJ
MM'=B;\CZ,;%H*KL"`ZX$\A%76J<X!YWQ:(D/<4C#+DE%)F]?XH3M&@R(F8%T
M^1E0<_?'*D8<N/MUD_D+59_/.R7]Z07^.U!\8R:>...,8XXYF;;&PE\@/5?T
M\UC6%JSY&OUBZF[86S9Y@4(I>/6^1LKYOI!?339IG92!"XIO5`RMOE78E%!$
M*F'RP7W3;#F*OBZ-L.%7C&:9<<P'0]FM^?JL[I2,<79=LV;7M&35XU-@LG3E
MT#0E#=Y21GZ1>NJM)Q1^K5&*=O54B.4RA(.LK$=)7`W;!^76PY"B]76+JAZZ
MK=[?3Q<;X):Y,[3LL<V`<VF`],<P4UW*BKP!J;42&H*,X<40:N2]-]);47U[
M).['!_9"M[60-<4*R(;R(!GK0J[S5#VSL9:*@_Y&._WIV2_R)M/DT\IU2=V)
MHU-,QY`:W,F3);FP$_KV@4!?!7!XP%;XL@I%QY)0NMYD;%-Q1IF'$2&Y<W0B
M&(])0<Q%@EH,Z#'ESZ?$;["NG\MNQ/Z6<8R:>.0M]/B-]A73^6W8G]+.4\]0
M796")TDVA@UR3NU#MU\IISIVAF>/4U^5A/A[&7D,R4WKI!#V441EH37IX[>+
MT@``#P99ED,IFB<`\89``V!*+PI#4Z^7;[36ZJ!NV;9["GKX6*LX66[9CK1L
M43EWX>4'M7ZF^R^2,I=Q&CN?LBLY_8H)/W\?89F)Z1_\]^DM_P!)EM__`''I
M.\],_/-'87>G=%G[T\+X\0[/KZ@]02=ITY8I^N!-_6D/KW3XMIG<&*2)M)1K
M*(^,3=6`ZWJ;U=,DVQ\7F?$ILZ4I-I$\'R8B9?-]M!^I57]6>HIZM=A;"WO<
M>#5(UUUA\ZOBSZAL,\)Z/WU]H_<P'N-&6ZJ%)[&3I":&L32;9<D\P#B>C3;`
MS4P:<Q4=K$R%PX6Z`^*'2&UZHVM_J/5U;TM*ITN^VB"ZZS-\];DZ]?52:2I+
M7$T4NTK4M[7W=FNK-+%KH9I6C]'LG:*I3I"BQ.RAFG],_6!VJ*HD$C`\$(6C
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MT;@-1H4ZZ17R.!B6V)0,=/AJ`HJ'D^,76P4%8!_\6:/D[Q_<!D;XN+VP3HOR
MT*3&D96,L'QQQQC''''&,<<<<8R%J#_D8[_>G9+_`")M/DT\A:@_Y&._WIV2
M_P`B;3Y-/&,<SB]5G^D*%_S#]-7_`/2'4_FCO,9MT+S!;!H6G(I:BGH59OWJ
M?VA1EEKK'"%0"#&=T(%[NN8B5'F"")6<-`C=M]):YM-5FB30@JSK"R'`NX["
MO-#L@S-X^'=*Q-UATW>1":NKZ@U=ZU*?T0NO,^Z:!.`>;-FGI[PJHW;&\T86
M66%"TBXUM@*\RD_4\3JH_P!7$?)_4&D7N]^#X!/C*V^H?_0!O+_P\V9_]*NW
M/+?ZMA&U"5+T2YZ[R#T#MZBT_=G=XQUP,?53<EG6M,+[S[9*JI(GPS@48.)E
MM3O5(V!6-HT7WA^#N\Q7#U]71,P&Z&.]J^SMB75]O7SJFV`@[0JM`<FNLRRQ
M#(1M?8E\W"SC3((Z&)8)(XN'+CI,D>3&$(TB%/A2,\65@RX,N3'VJI8.DE)6
M5;6M[ZQIZ=)1-8Z=V`J%`I?YIQ\-?X1E\K58US,Q^P0",!2R)P&HDYUK+Z-3
M2@?4B@6Q?BL4</*41/B5V7T=U-KM#/3?85&M1T[6TOF)U$M:R[ZAAKJLT/*L
MRC=5-9.SE@J)&6;D`@Z_/"\@;M;M+!%Y'AE`D'<P/[MG''OSQ[YO?5EFI%UU
MC7%R5D;^<U;VTAJ%FU\Q^VEPWS@2'Q?'-2F;]G8(`H\*]U`E8$_VTV+&EX/Q
M'PI*!#F8LT?'`^E=FN]M4\Y-5@F_G`>%;:;]5E`G^VB!7PZ12F]>QM-UD$^%
M"0!L/+\V:W0U-<]RS1\A<S[5[PP3RIZ<2*3//M9#]NLZ>CBE>FS4VG]\5%=G
M71I.U?L2YGMRTD,5C@BUQK7W7GI531P392Q&AE^L4=3L&NB\<-*->Y*Y7KFF
M7E,8`)>LXJT9COT4:HVNH+U$T>GKYJ\"BUF.]-<NS5F?CL2NPL[#:@FD?1,U
MWV36C&56>62)@`UZS:X)8I<RYEX'U*D";48$,#FO3P^4)SW/\($J])=:[.QN
MM35GU.TNWM11DLZS8[>[H=%7O)'+'/3N*BC<2;"%W@A3UTCT\VPGHBJ*CM*B
M_P!T]=!'(P=%61NUTC664J2"&7_+"GR3QS($#=W<,]@/'''/@&2F><?5GU`]
MGR^Q_IU]+BM'"T4AL1Z87IX&KC%$%*MTL$$VNW)5MKW(7L@:?!"?!G"<SH_Z
MQ)6K2?2T(BK5ZTV/LZE]5./"<Q"XG/GHXYY)O3SK;#L7JG6S9LE1`?*AG])_
M3LUAKZNK1%5D^J=FT+K!0*[8RK:K(HPF.S`W<PR[(7??1!;ZL<E<,1ZV4J6E
M&*N1'P8R3F#5[TD*[K^J.WJ'(%6HR=6J(!WP#>Q)2`LA4Y2"^Z>GUH0:)^TK
MB[!'!QWN)@B0+3_@X>'XPG/FSY'RDJ5GR]^A_BOT/IZE>[MM>*NILZ*M4J6M
M5K=?3&ONF;8Q1FTURI;C6&_`^R^5L1+2GC=*,2F=)`XR*HV9&*QMW.)2S*[L
MW>O"$]O:RDE3V=P)8'ECXXS7OCCCG/&2N..9F[1>KCI'J*_V[6%KV7AZNE&4
M"R7O9(X5.4H@\&0C"\!^K]=O#(XM:DLR=KMCUB,WM^OU`83'ET=4NO6QS*X%
ME6S*9=ITRY*W]'N-74UU[8ZR[1J;>)Y]9/:KR01WH8TKRM-6,BJ9(C#;JS)(
M!V20V8)HRT4L;M0LD;LZHZLT9X<*02I/(X/'V/((_400?((QQQQR*RO'(6JS
M^>=DO[T@O\=J#Y\%R['5C2E-;*7:8*_/`#J>AOSW<JS7TY>8'=?^CRIXMVE$
MW,%E'!4,4^%:W*KC,OKS467/CA#<IFI$R$!/0"V2"]"=BU[:M1OJZ%E,?*[@
MD=FG]`)(]FXDS$[K#;2*K7](/8DWYKMTL1)D_#.U=,'@;/6G5A&$1'F!/Q3.
MO:3WC8)(ZC9+K&W+4YEUB7H-:UMPJQ_.V:CWX(`K,)&:6G&UA65#'Z7:Q<>H
MG=1ZB=_I]P[RI?M]^T,%)_+PQ`_/G]AR]G'''(W*\<SLL_<U@2O4VU5T9&B?
MBEB[M;-B[K;R^"G;;92(DS61ZO!5?Q_%K#9`BH$12*1"5C>&F87^>YR(TP:M
M3BPU$DW!6Q-RT3YP$E35IC2&>9:T`E.RZ`95-?<)(8=G:02LYD5,PX+09@RQ
MNQ88`:RR&C%&4-"EX!QTBF*<TI&E25T/EAL9A,A^K2_%M6=TK9DL^K=C7-0^
MC)K=E,K)(E]5OJ@,"TC/S'<FGET!Q=]74U-5W:?&@=6A-BFD)AJ>!BE[`U&-
MG5]6DMH&9YNB.D^SDV]JJM5T<+:H2XENJ[/-)HS9_7R#&4]<+G4!U:5U8Q*P
M*_P2;PV#P"0:&8>&2G'>5,N!BPX["J5YE9/8H_\`"%&WGXXQE.J3V`H<4FF8
MI2[*C&R<MN;`$L4<A9";#SY!QF^+(,!Y^/#(,X\G>$5$SH)0;*Z]?."<.F19
MT7)EC2,.7O+GUDM=OO\`*6_%-&_WO%!_R,=_O3LE_D3:?)IXQD"Y=J=8,!:$
M`S;'T+A.DAQ0N."Y;@KW&6("0<D1"-%(0[NQ>)DH<(F,("(4FX,.2,/DG!&"
M7EPY24+IG\V6B^LL9K0*8V\(W';F'/L;;!/U4'>@(6&G\=%BMMMP-=3JA99Q
M5DYZCDWW!20:C;C(N(R27O4X.&1(00@?S,Q^-/,$K:;48]:/4"W<7`357M;7
M;6^GVO5KB/@;2K@<\+[#:]Y;;OVOMAX8:M8ZOAQ*QC7]W],BP5".U0H;!%LF
M%;Q"6MD@BTM1B=CV375U?4%\$IJ8(.KJJN'&+JRLKHR$$7UU?"0L`T,"!!AN
M",.$!Q`Z-&'C!@^-'A0(4?!%BX,6#%CQ]>H_A_HVZ4Z?F>5YUW/4E>G)M-?<
MUU=?Z(AJS;N.*O'/++/(\]^C=UUR7BM4LZZ57K-(TQFC@A;4OKR@`#TX2P1U
M<_B%A&22``.%974?4P<<'CC@GF....;+EG'(<2G=+0O4HUU,/3<L)8F3HYO@
M-CE&P^*7!T@CFOOTVY6&!AG&)<.-EFY8T.7(QQ<>7MG[X(LG-UQ^<>#+VZS'
MS,W9C>'!HQZD'IO,A&N<+XNWVD[4:XNY^:\=$,+1U<--I:.V'9>QC44SJK/!
MDI-(H%7,CR\QR^=/!#D\<;9C[TKA5^?-\^2ZG8;REM]7JZYMW[6@ZB%>N)(8
MC(8M%L)Y`))Y(HE*Q12,`TB]W;VKRY52#I&T;N>U5EBY/!/',B`>`"?N1[9M
M0P^IOHBE6<UUG8.TE"UMX5EM+,XK"L.[J=3JP;&!LS-.0Q6"8V&WZ)[[:E7+
MHA(>K92NL"/-242]Z!9Y663!M`1YQ9<[_P#JN5/:.AFS"I`HG8E6K/:S3K<)
M5UYV3<^VN8NF;-\D-)=@;L0#4,*/V*+7\KCK7KZNRD]#&/M&JC=T,%UU6=%A
M.9B.83#D77LW])!#8W8?)DB9\NR&U-T/(D@"[_*I#+6-6DAFJFNMAUW+[99W
M8RG6WK'KM2]MQFV,;.KSZ7>C+ZC2Q]?,ZHNA*@>LJE64V^G_`'/-I!+<7N\5
MR)A@UF$0%4L]MO>+=$,EK'=N(2E"1YKLP^]:QWK>*K/[R`A/(K#&":\@NX)L
M5EYI`PG1_P`,^F*N[T4-J*VVW>720-/;V)AUVLWZPPI-.(X((9/E(=X4>:2S
M/;C6C#,8ZCM)&L=VQ<F:.0J5$8$AX5.7>+D\#DDCN,?(`4+]9'U<#S8?T\/Z
M`-&O^'FLW_I5)Y&UA[NI&B8SU>U;IL%3](6TW:DK&[.M?:SG.N@]@N6TS#0]
MX:XXURJU%^FXA%F!UJ'I1K:3"(F!/;2_>P'YHP,<T^!<T]279AT276!0T@TV
M4VP$85VI7U4UY76998ADT(P+K`$J-0&F01T,2P1B(@P((QI(\F,(1H\V!-CY
MXLK!BSXLF/K&WJAT9]8_T^-M:GP#G$T8(TZPN"B`0(GN+:RV!5'>+;%=*PD5
MT$')1GYSO:0N@)X08-[FC0PC-%`I0XQ,@DHF]VJ.HW/4-W5;A?4U6TZAJ169
MD,+K#!#U-1V#S&*>*:"U"\51H9J\@5)J\\BB6,D,,56>.)7C_32(D#R.2863
MCD$$'EN01SP0/!S1_P!0/;4.M:U9^VN.SZ2HVZUWUIW5H-EKQBIE^>`Z_<FX
M5$5-8LQ657L-8Z@0,=:V=6[K$D'D=DA"._?WKR/\Y1V/-BK`+V&N33BRZXM;
M9K=BQ+<U-8B<BHKK);!+NI==+%#&['G`XE+W]D<J,USIH_E`QK0&A:!;%HYE
MGJ8T?L/&NYN8TA,HUGEEZ5Y+DO!2TTH#TT;GUS,#7VB^WHV!*LMK7Z'L5L93
M]QK]%[@4_'NHTZ/F'52MD/78Q62'KUTL]C7;!=2$+(KOX7H(9B<L=)ZRK"^H
M?_0!O+_P\V9_]*NW-'Z3^'U77ZJ3ICJ'4ZRQ)L^J]OKXMR==I[&RL:._K>G(
M-;M=/MQ'L7K"-K%JU36O<GKTMJENI<ADL07ZIRI[3,XFB=P$@C<Q]\@02*\I
M=)(^4!Y`4-RH+(592`5;(MO2@*=]0`[ZMM%,SN7DU);6X=%?&N=/LJMF*]_F
M'I!Z<CC&^;K$0#.:SV_A9DR.*+_+""7_`(C=2<''\&0\=)47175CUB-%+2UB
MURLV[=Z-#ZZN:Q:'J%[MROOK-T\H_,2SFZOEY@?DWYIMMG$&I8^;#40+!/F\
MS3YS"%^!]M-3))*-)S=Z`:4W*SWM=GJP.S=``CBH/U6;_IJ)'7(I"&/R+&NE
M1:\Z^),^1B)E#$GN>*)E8`";5*Q2\(^<SS#$T0+!BI$(*/L+M35K!>.L&Q]*
M*<P..:K@H6X*M62#%(FQ%^"P6!7K$IAIAV4-'ER,8/&(EXV8G('BB<W#"Z9\
MD4?-S]<<;+);GI:AN]5TMTMU)-;K+IJ73/IVJ-FNJZZ:?IC2:[=,%FIV1/%9
M%#722%6A)&LA`/#DK;CG:.2:>$*?4:;E6!^H":1X_LPX*]SCW_3/\>T>E'ZA
M!+85"VG?]E=@4/%#+;<&&_61>>9U55JUHNG%XZ[:W[+ZXU\R"0<9=Q%6E*2;
MNZ+[J=F37>3E=X3(*CV,\"1`P]*U1^LEKM]_E+?BFC?[WF=OI%H"E5`[>NK4
M`3["B5KM_6*`E`OCR93V523O3-].Y=7!/N9J81,$?;@XZ'#^/+$)Y.9\C\1/
MF2I63+G[W4W.V(8-6:!+6\IU\'M%JZV3K[5JRD,3W-K-?*,&P6PE74`&F'7H
M:AV<17PZ^1LZ,R$Y`]"9YLF$(SP(H_Y>7CD8/@G7&HBN_$6YI>F]?#7797M+
M3T^NC%2A%ZVSHZY:L+$O#2K-+/87UI9)8X%D=Y990O=)DI6D*U%DF<GL61I'
M/<QX1G[C[L>`/``)X``'MGF^#^H%2MUZQ_\`R#JB>+PUZ#;+[);L;GZEZRT<
M!L1<@/MT92>L5`:$ZK$$Y&*MQ=G,PK-.*2E#:+,P=(U7"C/9W=RY1%KI<.9%
M?6+T5/Z>]G_^RSU#?\F'7G3*?KG/6"=+!D3F%E8F6PK@MYW.0A'=>"D+'ONW
M'>\;+RJJWG*L,Y92<;_8;)@1EDNT.)U<3\00(?=G0U`GM1?N?HJ?T][/_P#9
M9ZAO^3#KSZ9\4*VMJ=#68M9!+#`_6G3LG:TZRP!*W26VT\"5(_E*TL$`@U*2
MK',\\J^MV,_X?+X=)G:RI<@D5Y1]N#YGCD)8]Q!/+D<C@>.??-AN...<VY+X
MXXY1HKOS5XS+M?!Z(EH3S>I=WTOKB>7>GBK1!JUKDV%"TP1IY2JB.TVDOX,4
M9Y,7_5Z:#;K<DU,D3V8U-\Q63.N@C3#!8R\O',RI_JJ4*&PB"3`C6FOK8N,!
MZ7\V%2M!=`.I;&V7]:>J2BF7KVBWK+*EV)EV:I.TZ.@Y]?1=ZK,)T3I\DZQ"
M%.6*92%D=0MJ5[<6I<EQ*B`V5ZO=FPZIP!S>^:X6$1)YES&/PF)^(OK#?&PJ
M,+]M/2"BB76&-Q"6"NM"PP#F5,#8<8N648S%J\?4N2*4WF]/&B)][(=149'W
MA]5D;N*YOS67J5>7W>K*/9+%I^LFUU:CRE6YU#9(>Y59/TF`2P-(B=9T.H\(
M0V&=TPL%R=ON7=W?C:*E.SUJ72],(U;2SA&]:'L'SL[96:X=B4"J)3%:NJ0N
M35G2D:;6*Q2=P&]0HWM=::];!]B@O5NRK6I]NP*%DG,IQ"[>LZVT^L[&WEL>
M&`'H]MNUK;&"F`O(L2R"2QWPL%F+"TQ30]9$VZ95ZP>9`&OE*!V-F6$T.QL`
M^M%6*8*S<0_QU[V#YU3H-%T8FHZ+V,>@&QV=#IO6>O/MI9!5EV5C8[C?6;7R
M.OEK+:9#N:VMKR7Y["BAJJH:JDS-((266QZEA/5[$:9^`@^H*J1Q!>Y@>W^K
M+D(!]3M]7'C,Z_3DI6K!%4=]RP"AA`WKZBB^E[;;,G(1QHEA3=CW-Y9[QE!%
M5;-G2PM124,Y=+:KHPT;A\G>Z?&"8WID>&B'+:B&BG''-KV%R387)[<AD_%8
M"))9GG:"M$BPU*JROPQAIU8X:L"@*D<$,<<:(B*BV$4(H4<>/N0..2?+-P/=
MF)8_F2223CCCCF'E6.54N76^%=MP+!EVBAS=-2=5-MM;[.4\Y=@$,#'"V1:-
M8Y76*,D@<<+/$#]U6GWD:=+PV8(P"II==R`<<GOGFD`MJ^.9-2W/2G%BLYBF
M6.:-)%)5T$\$D#NC*0R2*DK&-U(9'"N/(&>,H8<'R.0>/SX(/!_5R/(]QG3J
M[0%*J*_1JM0!/L*)6J<LH"4"^/)E/95)."PEU<$^YFIA$P1]N#CH</X\L0GD
MYGR/Q$^9*E9,N?OW'CCEAW>5WDD=I))&9Y)'8N[NY+.[LQ+,S,2S,Q)8DDDD
MYZ``.`.`/``^P'Y8XXXY3C'(%VIJU@O'6#8^E%.8''-5P4+<%6K)!BD38B_!
M8+`KUB4PTP[*&CRY&,'C$2\;,3D#Q1.;AA=,^2*/FY^N.-EGKCEZM/)5L06H
M2!+6FBGB+#N420NLB%E]QW*.1[CQGA`8$'[$$']A\'*(Z!ZQV/K!7EB!;6/*
MC2]68[5O9;@T*Y0Z;SM]CX-3M::KNVP&\VR`%\P?=K0OJKK2L]@:RF*>==N[
ME'=&V?X<F%B'#[W<<<O7[L^QM2W+'9ZTHB#>F@C0"&*.%`J#PH$<:C@>XY]\
M\50BA1SP.?N>3Y))_P"3D/ZC[7:MZLV3OHM[.;*4#KDQ6'MTJV6@`+XN.NZA
M-/-<9-&-+*\QV`GB[!8UZ<S).1_KNP$;HUA<$T%V<$9Q6>L_R:634*%\WJ&;
M]:*77KTKUE36ZFI=M60S;A^G/\W*^K+8ZGGQX8/9O4*U>8#'LBFJN14\5]J`
MBBALE\!`D?`B!L\E*^2APY&;'-/'-7/3&DDZJH=72C:G84;VEV`KQWJD=.6;
M2K26%2C:N2=8IODD,JB=G'>X5QX(O^M((&@'9V,LB<E6+`2=W/\`C`Y'<>/'
M\,<X'T5/Z>]G_P#LL]0W_)AUYSW.!]%3^GO9_P#[+/4-_P`F'7D'\3_[BO\`
M[LT'_C]5Y<I?VD?N)?\`L@S8;CCCG-^2^.423O3<U(1B.XQ->KK((F[SW,N7
MO>1-7,3:Z:?G\IB5'YN3T:Q*M\HUF)V8%8BT:O<`<@N>5Q6;RLJRG]99PV=A
MB01-[>.,91";H%J.I$0%F2`%LPY%6IXJ+Y[=-G=J9(-BA(#S8=T`VZU4WQ<N
M59O.S5^TK)?;6&6O;X)]M7#99OP]X6[RVC@Q:!W>J@6K]0UT05U;MC^;UGF,
M<ILS66]L]ROUMF"HH+5'0Y9#]:#78=AVO/[J28%0NIIY:6:='0T"*M=)&)72
M.D$5:@L+@'!1,*4P?%##`^8+(QOE<V#XB`0C9(DO!\M'R89&'Y:/FR8_E<&7
M%FQ_Q?QXLG3OXZ]O'36BJT=R,1&`^,GYC,'P)ZQ2`YD9P&?IX!2"TP-_'[`9
M&=,_D;-.$IT/SGZ9/.";FPS.GGQ)A0<L9C(,@TEJ6G0P$#+5E7LF%V,F3P`Q
M*K-/:/&>&Z.<:5!QQRPQ7R1<*D,*OJVJ*?CSV[1QJ](`Q_B,PX=.)X.70ZOU
M*LL-E8$REZ4,!\4WS`ZS\=4)6/#GR_!026+)@\Y`'7SDPYH!*%(Z>?\`QU[X
M_EO,>3CP2\,B/BEO'5%?X>BQUPKV/%D4(H6"$EXB!?&1\0EWN$RAXA8ITG^"
M+)&AR%L#*^08Y1;%(F"($R5USR8_3+XYI32EM'AS1ZQ!SCX1"=B(9XV4H6)X
ML>:,(%`8N&#U+3IWM@Z$'""Q\$0-^$%08\/IUB0L/;OE[9&,C_ZMNNWW!TM^
M%B-_HN/JVZ[?<'2WX6(W^BY-/'&,A;ZMNNWW!TM^%B-_HN1U&1-.)1/J'QU%
M270AY86Q7[X)%1*<3IB+(X_P59^F:3)6L47I$%C^^"1D(><WP.3Q)PX\4COE
M\Y,>.UW(PRTW768H5-=P<KP1-8)N"=FQ,;1@Q>/)/L]=B<J#$PFL<,23)=;&
M:<1$N*CPBDZ/W7XLN9FC):9B7V,ACS3&G9&?Y>H2-24R`G+C\.,!0:97Q$+Y
MZ1)2@392!Y='`)<^0SH_45`@1NO\&.>OQVTN.DP>TA@C]>@:F:=%64.G1:8I
MSJSFL!.1'"R:=4XD^-X$3V85/ZS<,E<Q=L/C$33&F#US]/E8>7,'R=L<GMAG
M"LL^1%76^G$SJPQ02="Q!F2'*AS5Z;WR%`L7R3:7IT/3AL8CVDYX))B8K%9)
MAJ?CE>9$G!X##,/>.+7PT*%W$?5J0+*`S<(9.QE5[-.D#YN1C9I.7-((]FK)
M)SF?$HQFZ,F;QE=VW/$RL70ID'R#Q"1`[1L^7QDZL9U?ZMNNWW!TM^%B-_HN
M/JVZ[?<'2WX6(W^BY-/'&,A;ZMNNWW!TM^%B-_HN<<8H/6@"(*G"=$4Q@&AA
MLXL0S=:H2LW;#!'1LLR7EZX<0#OER]L>##D[^,>/IVR=_/CQUZ=>W;SX\>9Z
MYUYE5@S=`QBSV*=(@8Y/B3WBPC)H-CE_^8TF'EB$O92`_L5%2HLR1@G!27:6
M(GX\GCK-@R/&/'_`QE93-.Z>-$%EA0D"F\&.O_F0\M9%*1$/-*%C(<N'80T8
M2DBUTCVR#FI?!]/)P%CQ=IQM$8.OR/3I#8ALS+^HU,TZ*LH=.BTQ3G5G-8"<
MB.%DTZIQ)\;P(GLPJ?UFX9*YB[8?&(FF-,'KGZ?*P\N8/D[8Y/;#.%99\L@:
M&J9;PMT<:GQ\V![[B.[3B-E#K-T)>0"UA3@OC'X9"A;VWH,6(^`+#QBO@<>&
M%BZ=.G7QV\?Q<YP?5J0+*`S<(9.QE5[-.D#YN1C9I.7-((]FK))SF?$HQFZ,
MF;QE=VW/$RL70ID'R#Q"1`[1L^7QDZL9U?ZMNNWW!TM^%B-_HN/JVZ[?<'2W
MX6(W^BY-/'&,A;ZMNNWW!TM^%B-_HN<(QT?K`JB)!LU1=,1X.#/`B=?DJF3)
M,F60+D8@<.+@1(Z_DD329@O/@BA<&-CR2)Q&;%B8.G?-FZ=?-A.<.>`"6<7G
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M\7[#-35Z>E#YD]<Q8\XKX+L.\BIY8#BB9ADDK-$R\48%/&QO<`TXX9G!2/;%
MVGAIQ2?,&2(DF5FR]V,[H'+03P@4<&9>V<:9&P2P_-WQY,/;-!(QL4R)E[8<
MO7IEQ=LF#-C[^<>3IUR=//GSU[]>O;QY\>.1YQ80,.7`HA>$8<D<2"%CPPN/
MFE2YV7`.%Q,,&%ARS2&>5/F9,4;!BZ=Y4V3(ER.W7SFDY\V;OWR=N4XQG__9
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
